 
     
   
 
 
Cover Page 
  
Official title:  A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to evaluate the efficacy and 
safety of twice daily topi[INVESTIGATOR_552278]  1, 3, 8, 20 mg/g for 8 weeks in adult subjects with mild to severe 
atopic dermatitis  
LEO Pharma number:  LP0133-[ADDRESS_725834] number:  NCT0372572 2 
Date: 22-Aug- [ADDRESS_725835] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
Updated Clinical Trial Protocol 
LP0133-1275 
Phase 2b dose-ranging trial to evaluate delgocitinib cream 1, 3, 8, and 20 mg/g compared to 
delg
ocitinib cream vehicle over an 8-week treatment period in adult subjects with atopic 
dermatitis 
Phase 2b â€“ dose-ranging trial 
A phase 2b, double-blind, randomised, 5-arm, vehicle-controlled, dose-ranging trial to 
e
valuate the efficacy and safety of twice daily topi[INVESTIGATOR_552278] 
1, 3, 8, 20 mg/g for 8 weeks in adult subjects with mild to severe atopic dermatitis 
This clinical trial will be conducted in compliance with the clinical trial protocol, ICH-GCP 
and the applicable regulatory requirement(s).  
LEO  Pharma A/S  Trial ID:  LP0133 -1275  
Date:  22-Aug-[ADDRESS_725836] n o: Not applicable  
Version:  3.0 

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

&OLQLFDOWULDOSURWRFROVWDWHPHQW V
$SSURYDO VWDWHPHQW/(23KDUPD$6 
7KHIROORZLQJSHUVRQVK DYHDSSURYHGWKLVF OLQLFDOWULDOSURWRFROE\XVLQJHOHFWURQLFVLJQDWXUHV
DVSUHVHQWHGRQWKHODVWSDJHRIWKLVGRFXPHQW 
06F6WDW  
%LRVWDWLVWLFV/HDG*ORED O&OLQLFDO2SHUDWLRQV 
 
 0' 
9LFH3UHVLGHQW0HGLFDO6FLHQFHV 

0$ 
&OLQLFDO2SHUDWLRQV/HDG*OREDO&OLQLFDO2SHUDWLRQV 
 
$SSURYDO VWDWHPHQW VLJQDWRU\ LQYHVWLJDWRU 
7KHVLJQDWRU\ LQYHVWLJDWRUDSSURYHVWKHFOLQLFD OWULDOSURWRFROE\PDQXDOO\V LJQLQJWKH
6LJQDWRU\ ,QYHVWLJDWRU&OLQLFDO7ULDO3URWRFRO$SSURYDO)RUPZKLFKLVD VHSDUDWHGRFXPHQW
DSSHQGHG WRWKLVGRFXPHQW 
7KHIROORZLQJSHUVRQKDVDSSURYH GWKLVFOLQLFDOWULDOSURWRFRO 
0'3K'03+  
6LJQDWRU\LQYHVWLJDWRU 

$FNQRZOHGJH PHQWVWDWHPHQW LQYHVWLJDWRU V
(DFKSDUWLFLSDWLQJLQYHVWLJDWRUPXVWD JUHHWRWKHDSSURYHG FOLQLFDOWULDOSURWRFROE\VLJQLQJD 
&OLQLFDO7ULDO 3URWRFRO$FNQRZOHGJHPHQW)RUP RUVLPLODUGRFXPHQW 




PDD
PDD
PDD
PDD
Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725837] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Protocol amendment summary of changes tables  
Document  Protocol version  Date  Type of protocol amendment  
Amendment 2 
(substantial)  3.0 22-Aug-2019  Global  
Amendment 1  
(substantial)  2.0 09-Jan-2019  Global  
Original protocol  1.0 22-Jun-2018  Not applicable  
 
A protocol amendment summary of changes table for the previous amendment is provided  in 
Appendix 7. 
Amendment 2 (22-Aug-2019 ) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
or subsequent regulation.  
Overall rationale for the amendment  
The main reason for the amendment is to remove the recruitment cap for the number of 
subjects within each disease severity group  due to slow recruitment of subjects with sever e 
atopic dermatitis . Miscellaneous other changes/updates have also been implemented.  
The table below summarises changes made in each section and a brief rationale for each 
change.  
Section no. and name  [CONTACT_18054] 1  
Protocol synopsis  
Section 7.1  
Overall trial design  
Section 7.2  Recruitment cap removed for the 
number of subjects  within each 
disease severity group . Cappi[INVESTIGATOR_552279]. Cappi[INVESTIGATOR_552280], 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725838] the 
change in the full analysis set.  Randomised subjects not 
exposed to IMP will not be 
included in the full analysis 
set. No bias is introduced by 
[CONTACT_552295], as th is is 
a blinded trial.  
Throughout  Minor editorial and document 
formatting revisions.  Minor, therefore not 
summarised.  
 
 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725839]  ................................ .................  26 
5.3 Trial rationale  ................................ ................................ ................................ ...........  27 
5.4 Justification for dose  ................................ ................................ ................................  28 
5.5 Ethical considerations  ................................ ................................ ..............................  29 
5.6 Benefit/risk assessment  ................................ ................................ ............................  [ADDRESS_725840] description  ................................ ................................ ..........................  42 
9.2 Administration of IMP  ................................ ................................ .............................  42 
9.3 Treatment assignment  ................................ ................................ ..............................  43 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725841] treatment  ................................  43 
9.4 Background treatment (emollients)  ................................ ................................ .........  [ADDRESS_725842] to follow -up ................................ ................................ ................................ ..... 51 
11 Trial assessments and procedures  ................................ ................................ ....................  53 
11.1 Overview  ................................ ................................ ................................ ..................  53 
11.2 Assessments performed only at screening/baseline  ................................ .................  54 
11.2.1  Demographics ................................ ................................ ................................  54 
11.2.2  Fitzpatrick skin type  ................................ ................................ ......................  55 
11.2.3  Medical history  ................................ ................................ ..............................  55 
11.2.4  Height and weight  ................................ ................................ .........................  56 
11.2.5  Body surface area involvement  ................................ ................................ ..... 56 
11.3 Efficacy assessments ................................ ................................ ................................  56 
11.3.1  Eczema Area and Severity Index (EASI)  ................................ ......................  56 
11.3.2  Validated Investigator Global Assessment scale for Atopic Dermatitis 
(vIGA -AD) ................................ ................................ ................................ .... 58 
11.3.3  Scoring Atopic Dermatitis (SCORAD)  ................................ .........................  58 
11.4 Safety assessments  ................................ ................................ ................................ ... 60 
11.4.1  Vital signs  ................................ ................................ ................................ ...... 60 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725843] assessment of local tolerability  ................................ ........................  64 
11.5 Pharmacokinetic assessments  ................................ ................................ ..................  65 
11.5.1  Blood sampling for analysis of systemic concentration of delgocitinib  ....... 65 
11.6 Pharmacodynamics and pharmacogenomics  ................................ ...........................  65 
11.6.1  Overview  ................................ ................................ ................................ ....... 65 
11.6.2  Skin swabs  ................................ ................................ ................................ ..... 66 
11.6.3  Skin biopsies and photographs (all sites, but optional)  ................................ . 66 
11.7 Other assessments  ................................ ................................ ................................ .... 68 
11.7.1  Patient -reported outcomes (PROs)  ................................ ................................  [ADDRESS_725844]  ................................ ................................ . 79 
13.6.2  Overdose ................................ ................................ ................................ ........  80 
13.6.3  Medication error  ................................ ................................ ............................  80 
13.6.4  Misuse ................................ ................................ ................................ ...........  80 
13.6.5  Abuse  ................................ ................................ ................................ .............  80 
13.6.6  Aggravation of condition  ................................ ................................ ..............  81 
13.7 Follow -up for final outcome of adverse events  ................................ .......................  81 
13.8  Handling of an urgent safety measure  ................................ ................................ ..... 81 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725845] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
14 Statistical methods  ................................ ................................ ................................ .............  82 
14.1  Sample size  ................................ ................................ ................................ ..............  82 
14.2  Trial analy sis sets  ................................ ................................ ................................ ..... 82 
14.3  Statistical analysis  ................................ ................................ ................................ .... 83 
14.3.1  Disposition of subjects  ................................ ................................ ..................  83 
14.3.2  Demographics and other baseline characteristics ................................ ..........  83 
14.3.3  Exposure and treatment compliance  ................................ .............................  83 
14.3.4  Testing strategy  ................................ ................................ .............................  84 
14.3.5  Analysis of primary efficacy endpoint  ................................ ..........................  84 
14.3.6  Analysis of secondary efficacy endpoints  ................................ .....................  85 
14.3.7  Analysis of other endpoints  ................................ ................................ ...........  86 
14.3.8  Analysis of pharmacodynamics and pharmacogenomics ..............................  88 
14.3.9  Analysis of safety  ................................ ................................ ..........................  89 
14.3.10  Pharmacokinetics  ................................ ................................ ..........................  90 
14.3.11  Interim analysis  ................................ ................................ .............................  90 
14.3.12  General principles  ................................ ................................ .........................  90 
14.3.13  Handling of missing values  ................................ ................................ ...........  91 
15 References  ................................ ................................ ................................ ...........................  92 
Appendix 1: Definitions of adverse events and serious adverse events  .............................  96 
Appendix 2: Classification of adverse events  ................................ ................................ ....... 98 
Appendix 3: Trial governance considerations  ................................ ................................ ... 101 
Appendix 3A: Regulatory and ethical considerations  ................................ ..............  101 
Appendix 3B: Informed consent process  ................................ ................................ . 101 
Appendix 3C: Subject and data confidentiality  ................................ .......................  102 
Appendix 3D: Record keepi[INVESTIGATOR_007], quality control, and data handling  .........................  103 
Appendix 3E: Registration, reporting and publication policy  ................................ . 108 
Appendix 3F: Insurance  ................................ ................................ ...........................  109 
Appendix 3 G: Financial disclosure  ................................ ................................ ..........  109 
Appendix 3H: Trial and site closure  ................................ ................................ ........  110 
Appendix 3I: Responsibilities  ................................ ................................ ..................  111 
Appendix 4: Short version of eligibility criteria  ................................ ................................  112 
Appendix 5: Contact [CONTACT_4111]  ................................ ................................ ................................ ...... 114 
Appendix 6: Hanifin and Rajka (1980) diagnostic criteria for AD  ................................ .. 115 
Appendix 7: Protocol  amendment history  ................................ ................................ .........  116 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version : 3.[ADDRESS_725846] of panels 
Panel 1: Trial design  ................................ ................................ ................................ .................  19 
Panel 2: Schedule of trial procedures  ................................ ................................ .......................  20 
Panel 3: Objectives and endpoints  ................................ ................................ ...........................  31 
Panel 4: Identification of IMPs  ................................ ................................ ................................  42 
Panel 5: Prohibited medication and procedures  ................................ ................................ ....... 46 
Panel 6: Sequence of assessments  ................................ ................................ ............................  53 
Panel 7: Fitzpatrick skin classification  ................................ ................................ .....................  55 
Panel 8: Calculation of the Eczema Area and Severity Index  ................................ ..................  57 
Panel 9: EASI severity score scale and area score scale  ................................ ..........................  57 
Panel 10: Validated Investigator Global Assessment scale for Atopic Dermatitis  ...................  58 
Panel 11: Clinical laboratory tests  ................................ ................................ ............................  63 
Panel 12: Subject assessment of local tolerability after IMP application  ................................  64 
Panel 13: Adverse events of special interest  ................................ ................................ ............  79 
Panel 14: Transmission of electronic data  ................................ ................................ ..............  107 
 

Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725847] 50% reduction in EASI score  
EASI75  At least 75% reduction in EASI score  
ECG  Electrocardiogram  
eCRF  Electronic case report form  
eDiary  Electronic diary  
EMA  European Medicines Agency  
ePRO  Electronic patient -reported outcome  
EQ-5D-5L EuroQoL 5 -Dimension Health Questionnaire 5 Level  
FDA  Unites States Food and Drug Administration  
GCP  Good Clinical Practice  
HBcAb  Hepatitis B core antibody  
HBsAB  Hepatitis B surface antibody  
HBsAg  Hepatitis B surface antigen  
HCV  Hepatitis C virus  

Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725848]  
IRT Interactive response technology  
JAK Janus kinase  
LDL  Low density lipoprotein  
LEO  LEO Pharma A/S  
MedDRA  Medical Dictionary for Regulatory Activities  
MMRM  Mixed model for r epeated measurements  
NBUVB  Narrow band ultraviolet B  
NRS  Numeric rating scale  
PDE -4 Phosphodiesterase -4 
PGI-C Patient Global Impression of Change  
PGI-S Patient Global Impression of Severity  
PK Pharmacokinetics  
POEM  Patient -Oriented Eczema Measure  
PRO  Patient -reported outcome  
PT Preferred term  
PUV A  Psoralen and ultraviolet A  
S. aureus  Staphylococcus aureus  
SAE  Serious adverse event  
SCORAD  Scoring Atopic Dermatitis  

Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725849] 50% reduction in SCORAD  
SCORAD75  At least 75% reduction in SCORAD  
SDTM  Study data tabulation model  
SF-[ADDRESS_725850]  Upper limit of normal range  
UV Ultraviolet  
UV A  Ultraviolet A  
UVB  Ultraviolet B  
vIGA -ADâ„¢ Validated Investigator Global Assessment scale for Atopic Dermatitis  
(termed vIGA -AD in this protocol ) 
vIGA -AD TS  vIGA -AD treatment success, i.e. a vIGA -AD score of 0 (clear) or 1 (almost  
clear ) with at least a 2 -step improvement  
W Week  
WHO  World Health Organization  
WLQ  Work Limitation Questionnaire  

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI
7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283
3URWRFROV\QRSVLV 
7ULDO,'
,1'QR
1&7QR7ULDO,' /3
,1'QR 
1&7 
7LWOHRIWULDO $SKDVHEGRXEOHEOLQGUDQGRPLVHGDUPYHKLFOHFRQWUROOHG GRVHUDQJLQJ
WULDOWRHYDOXDWH WKHHIILFDF\DQGVDIHW\RI WZLFHGDLO\WRSLFDODSSOLFDWLRQVRI
GHOJRFLWLQLE FUHDPPJJ IRUZHHNV LQDGXOWVXEMHFWVZLWKPLOGWR
VHYHUHDWRSLFGHUPDWLWLV 
6KRUWWLWOHRIWULDO 3KDVHEGRVHUDQJLQJWULDOWRHYDOXDWHGHOJRFLWLQLEFUHDP DQGPJJ
FRPSDUHGWRGHOJRFLWLQLEFU HDPYHKLFOHRYHUDQ ZHHNWUHDWPHQWSHULRGLQ
DGXOWVXEMHFWVZLWKDWRSLF GHUPDWLWLV 
0DLQREMHFWLYHV 3ULPDU\REMHFWLYH
7RHVWDEOLVKWKHGRVH UHVSRQVHUHODWLRQVKLSRIWZ LFHGDLO\DSSOLFDWLRQVRI
GHOJRFLWLQLE FUHDPDQGPJJDQG GHOJRFLWLQLE FUHDPYHKLFOHIRU
ZHHNVLQWKHWUHDWPHQWRIVXEMHFWVZLWKPLOGWRVHYHUH$' 
2WKHUREMHFWLYHV 
7RFRPSDUH WKHVDIHW\RIWZLFHGDLO\DSSOLFDWLRQVRI GHOJRFLWLQLE FUHDP
PJJZLWK GHOJRFLWLQLE FUHDPYHKLFOHIRUZHHNVLQWKHWUHDWPHQWRI
VXEMHFWVZLWKPLOGWRVHYHUH$' 
7RHYDOXDWH WKHKHDOWKUHODWHGTXDOLW\RIOLIHDQGHIILFDF\RIWZLFHGDLO\
DSSOLFDWLRQVRI GHOJRFLWLQLE FUHDPPJJDQG GHOJRFLWLQLE FUHDP
YHKLFOHIRUZHHNVLQWKHWUHDW PHQWRIVXEMHFWVZLWKPLOGWRV HYHUH$' 
7RHYDOXDWHWKHHIIHFWRIGHOJRFLWLQLERQ 6DXUHXVFRORQLVDWLRQRIWKHVNLQVNLQ
PLFURELRPHDQGVNLQLQIOD[COMPANY_003]WLRQ 
3ULPDU\HQGSRLQW x&KDQJHIURPEDVHOLQHWR:HHNLQ(F]HPD$UHDDQG6HYHULW\,QGH [
($6,VFRUH
6HFRQGDU\
HQGSRLQWV x9DOLGDWHG,QYHVWLJDWRU*OREDO$V VHVVPHQWVFDOHIRU$WRSLF'HUPD WLWLV
Y,*$$'VFRUHRIFOHDURUDOPRVWFOHDUZLWKÂ• VWHS
LPSURYHPHQW Y,*$$'WUHDWPHQWVXFFHVV>76@ IURPEDVHOLQHWR :HHN

x($6,DW:HHN 
x7LPHWRY,*$$'76
)LQDOFROOHFWLRQRI
GDWDIRUWKH
SULPDU\HQGSRLQW:HHN
7ULDOGHVLJQ 7KHWULDOLVGHVLJQHGDVDGRXEOHEOLQGPXOWLFHQWUHUDQGRPLV HGDUP
YHKLFOHFRQWUROOHGSDUDOOHO JURXSWULDOLQZKLFKDGXOWVXEMHFWVZLWKPLOGWR
VHYHUH$'ZLOOEHWUHDWHGZLWK GHOJRFLWLQLE FUHDPPJJRU
GHOJRFLWLQLE FUHDPYHKLFOHIRU ZHHNV
7KHWULDOFRQVLVWVRIDVFU HHQLQJSHULRGDWUHDWPHQWSHULRGD QGDIROORZ XS
SHULRGCCI
Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725851] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
  
Screening period  
The screening period has a minimum duration of 2 w eeks and a maximum 
duration of 4  weeks. At the screening visit, the subjectsâ€™ eligibility to enter the 
trial will be checked. The subjects will receive training in com pletion of an 
electronic diary ( eDiary ). Furthermore, the subjects will be asked to fill out 
patient -reported outcome measures ( PROs ).  
Treatment period  
At baseline (Day 1), subjectsâ€™ eligibility to enter the trial will be confirmed and , 
if still eligible , the subjects will be randomised to 1 of the 5 treatment groups. 
The randomisation will be stratified by [CONTACT_552296]-
AD (mild, moderate, and severe)  and region (North America and Australia) .    
The first application of the investigational medicinal product ( IMP) will occur 
at the trial site at baseline (Day 1). The subsequent  IMP appl ications will be 
performed by [CONTACT_552297] [ADDRESS_725852] 
IMP application for assessment of safety.  
 
 
Main assessments  Investigator efficacy assessments : 

Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725853] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
ï‚· EASI  for assessment of severity and extent of AD . 
ï‚· vIGA-AD for assessment of the subjectâ€™s global disease severity .   
ï‚· Scoring Atopic Dermatitis ( SCORAD ) for evaluation of the extent and 
severity of AD lesions, along with subjective symptoms . 
Subject assessment s of efficacy and health -related quality of life; PROs:  
ï‚· Atopic Dermatitis Symptom Diary ( ADSD ).  
ï‚· Eczema -related Sleep Numeric Rating Scale ( Eczema -related Sleep NRS ). 
ï‚· Patient -Oriented Eczema Measure ( POEM ). 
ï‚· Dermatology Life Quality Index ( DLQI ). 
ï‚· Patient Global Impression of Severity ( PGI-S). 
ï‚· Patient Global Impression of Change (PGI -C). 
ï‚· 36-item Short Form Health Survey ( SF-36). 
ï‚· EuroQoL 5 -Dimension Health Questionnaire 5 Level ( EQ-5D-5L). 
ï‚· Work Limitation Questionnaire ( WLQ ). 
ï‚· Treatment Satisfaction Questionnaire for Medicine ( TSQM ). 
Safety assessments : 
ï‚· Vital signs, physical examination, electrocardiograms, l aboratory testing , 
subject assessment of local tolerability, and adverse events reporting . 
Main criteria for 
inclusion  ï‚· Age 18 years and above . 
ï‚· Diagnosis of AD as defined by [CONTACT_85811] 1980 criteria for 
AD.  
ï‚· History of AD for â‰¥1 year . 
ï‚· AD involvement of 5â€“50% treatable body surface area  at screening and at 
baseline  (excluding scalp) . 
ï‚· Disease severity graded as mild to severe according to vIGA-AD (i.e. 
vIGA -AD â‰¥2) at screening and baseline . 
ï‚· Able and willing to follow trial procedures including application of IMP to 
all AD lesions .  
Main criteria for 
exclusion  ï‚· AD lesion(s) on scalp  at screening and /or baseline . 
ï‚· Active dermatologic conditions that may confound the diagnosis of AD or 
would interfere with assessment of treatment, such as scabies, cutaneous 
lymphoma, rosacea, urticaria, or psoriasis.  
ï‚· Known active allergic or irritant contact [CONTACT_552298] . 
ï‚· Use of tanning beds or phototherapy ( narrow band ultraviolet B 
(NBUVB ), ultraviolet B ( UVB ), ultraviolet A1 ( UVA1 ), psoralen and 
ultraviolet A ( PUVA )) within 4 weeks prio r to baseline . 
ï‚· Treatment with the following medications within 4 weeks prior to 
baseline:  
o Systemic immunosuppressive/immunomodulating drugs (e.g. 
methotrexate, cyclosporine, azathioprine, mycophenolate -mofetil, 
Janus kinase inhibitors, retinoids) . 

Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725854] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
o Systemic  corticosteroid use (excludes inhaled or intranasal 
delivery) . 
o Three or more bleach baths during any week within the 4 weeks . 
ï‚· Treatment with the following medications within 2 weeks prior to baseline  
o Topi[INVESTIGATOR_11977] s (TCSs). 
o Topi[INVESTIGATOR_73199] s (TCI s). 
o Topi[INVESTIGATOR_2855] p hosphodiesterase -4 (PDE -4) inhibitor s. 
o Oral antibiotics.  
ï‚· Change in systemic antihistamine therapy within [ADDRESS_725855] not start antihistamine treatment or change the 
current dosage regime within 2 weeks prior to baseline . 
ï‚· Receipt of live attenuated vaccines 30 days prior to baseline and during 
the trial including the safety follow -up period . 
ï‚· Receipt of blood products within 4 weeks prior to screening .  
ï‚· Treatment with any marketed biological  therapy or investigational 
biologic agents (including immunoglobulin, anti -IgE or dupi[INVESTIGATOR_12458]) . 
o Any cell -depleting agents including but not limited to rituximab: 
within 6 months prior to baseline, or until lymphocyte count returns 
to normal, whichever is lo nger. 
o Other biologics: within 3 months or 5 half -lives, whichever is 
longer, prior to baseline . 
ï‚· History of any active skin infection within 1 week prior to baseline . 
ï‚· A helminth parasitic infection within [ADDRESS_725856] of care therapy . 
ï‚· Clinically significant infection within [ADDRESS_725857]â€™s 
ability to participate in the trial. Clinically significant infections are 
defined as:  
o A systemic infection . 
o A serious skin infection requiring parenteral (intravenous or 
intramuscular) antibiotics, antiviral, or antifungal medication . 
ï‚· Tuberculosis requiring treatment within the 12 months prior to screening   
and/or subjects with a positive blood test for tuberculosis at screening*.  
* Subjects with high risk of latent tuberculosis (e.g. prior residence in or 
travel to countries with high prevalence of tuberculosis, close contact [CONTACT_4490] 
a person with active tuberculosis, or a history of active or latent 
tuberculosis where an adequate course of treatment cannot be confirmed) 
must be tested.   
ï‚· History of any known primary immunodeficiency disorder including a 
positive human immunodeficiency virus ( HIV) test at screening, or the 

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

VXEMHFWWDNLQJDQWLUHWURYLUDOPHGLFDWLRQVDVGHWHUPLQHGE\PHGL FDOKLVWRU\
DQGRUVXEMHFWÂ¶VYHUEDOUHSRUW 
x$Q\GLVRUGHULQFOXGLQJEXWQRWOLPLWHGW RFDUGLRYDVFXODUJDVWURLQWHVWLQDO
KHSDWLFUHQDOQHXURORJLFDOPXVFXORVNHOHWDOLQIHFWLRXVHQGR FULQH
PHWDEROLFKDHPDWRORJLFDOLPP XQRORJLFDOSV\FKLDWULFRUPDMRU SK\VLFDO
LPSDLUPHQWWKDWLVQRWVWDEOHL QWKHRSLQLRQRIWKHLQYHVWLJDW RUDQGFRXOG
o$IIHFWWKHVDIHW\RIWKHVXEMHFWWKURXJKRXWWKHWULDO 
o,QIOXHQFHWKHILQGLQJVRIWKHW ULDORUWKHLULQWHUSUHWDWLRQV 
o,PSHGHWKHVXEMHFWÂ¶VDELOLW\WRFRPSOHWHWKHHQWLUHGXUDWLRQRI WULDO
x3RVLWLYHKHSDWLWLV%VXUIDFHDQWLJHQ +%V$JKHSDWLWLV%VXUIDFH DQWLERG\
+%V$EKHSDWLWLV%FRUHDQWLERG\ +%F$ERUKHSDWLWLV&YLUXV DQWL
+&9VHURORJ\DWVFUHHQLQJ6XEMHFWVZLWKSRVLWLYH+%V$EPD\EH
UDQGRPLVHGSURYLGHGWKH\DUHKHSDWLWLV%YDFFLQDWHGDQGKDYHQH JDWLYH
+%V$JDQG+%F$E 
,QYHVWLJDWLRQDO
PHGLFLQDO 
SURGXFWV1DPHRI,03GHOJRFLWLQLEFUHDP
$FWLYHVXEVWDQFH GHOJRFLWLQLE 
)RUPXODWLRQFUHDP 
)RUPXODWLRQVWUHQJWK DQGPJJDQGYHKLFOH 
'RVHDQGPHWKRGRIDGPLQLVWUDWLRQ WZLFHGDLO\WRSLFDODSSOLFDW LRQ
'XUDWLRQRI
WUHDWPHQW$QZHHNWUHDWPHQWSHULRG 
1XPEHURI
VXEMHFWV$WRWDORIVXEMHFWVHOLJLEOHVXEMHFWVZLOOEHUDQGRPLVHG WR
GHOJRFLWLQLE FUHDPPJJRU GHOJRFLWLQLE FUHDPYHKLFOH 
1XPEHUDQG
GLVWULEXWLRQRI
WULDOVLWHV$SSUR[LPDWHO\VLWHVLQ1RUWK $PHULFD86DQG&DQDGDDQG$XV WUDOLD
6WDWLVWLFDO
PHWKRGV$GRVHUHVSRQVHPRGHOOLQJDSSURDF KZLOOEHDSSOLHGIRUWKHSULP DU\HQGSRLQW
FKDQJHIURPEDVHOLQHWR:HHNLQ($6, DQGWKHVHFRQGDU\HQGSRLQW V($6,
DQGY,*$$'767KHGRVH UHVSRQVH UHODWLRQVKLSZLOOEHPRGHOOHGE\
LGHQWLILHGFDQGLGDWHPRGHOVVH OHFWHGEDVHGRQWKHH[SHFWHGGRVH UHVSRQVH
UHODWLRQVKLSIRUGHOJRFLWLQLEFUHDP 
,QDGGLWLRQFRQWLQXRXVHQGSRLQWVZLOOEHDQDO\VHGXVLQJDUHSH DWHG
PHDVXUHPHQWVPRGHODQGIRUWKHELQDU\HQGSRLQWV WKHGLIIHUHQFHLQUHVSRQVH
UDWHVEHWZHHQWUHDWPHQWJURXSVZLOOEHDQDO\VHGXVLQJWKH&RFKU DQ0DQWHO
+DHQV]HOWHVW 
)RUWKHSULPDU\DQGVHFRQGDU\HQGSRLQ WVWKHVHOHFWLRQRIWKHG RVHUHVSRQVH
PRGHOWKDWILWVGDWDEHVWZLOOEHFRQWUROOHGXVLQJDIDPLO \ZLVHHUURUUDWHRI
7KHUHZLOOEHQRDGMXVWPHQWIRUWKHPXOWLSOHWHVWLQJRISULPDU\ DQGVHFRQGDU\
HQGSRLQWVDOOS YDOXHVZLOOEHFRQVLGHUHGQRPLQDO 
6LJQDWRU\
LQYHVWLJDWRU 0'3K'03+  PDD
Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725858] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Northwestern University, Department of Dermatology, Chicago, Illinois, [LOCATION_003]  
(until 30 -Sep-2019) . 
George Washington University, Department of Dermatology, Washington DC, 
[LOCATION_003]  (from [ADDRESS_725859]-2019) . 
Sponsor  LEO Pharma A/S, Industriparken 55, DK -2750 Ballerup, Denmark . 

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

7ULDOLGHQWLILFDWLRQ 
,1'QXPEHU 
1&7QXPEHU 1&7 
7KHFOLQLFDOWULDOSURWRFROZLOOEHUHJ LVWHUHGLQORFDOUHJLVWU LHVLIUHTXLUHGE\ORFDOOHJLVODWLRQ 
6FKHPDWLFRIW ULDOGHVLJQ
3DQHO7ULDOGHVLJQ 


$EEUHYLDWLRQV Y,*$$'9DOLGDWHG,QYHVWLJDWRU*OREDO$VV HVVPHQWVFDOHIRU$WRSLF'HUPD WLWLVELGWZLFH
GDLO\ZZHHNGGD\
CCI
Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725860] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
c) A visit at the trial site is not required on Day 4, a member of trial site personnel will call the subjects  
d) End of treatment assessments will be conducted at Week 8. Early termination: s ubjects, who discontinue IMP treatment prior to Week [ADDRESS_725861]  IMP application for completion of all trial procedures 
scheduled fo r the visit at Week 8 (except for the skin biopsy, if the subject ha s consented to have skin biopsies obtained), and they will also be asked to return to the trial 
site [ADDRESS_725862] IMP application for a follow -up visit and at Week 8 for a primar y endpoint visit  
e) All subjects will be asked to return to the trial site approximately [ADDRESS_725863] IMP application for assessment of  safety at a follow -up visit  
f) Subjects who discontinue IMP treatment prior to Week 8 will be asked to return to the  trial site at Week 8 for a primary endpoint visit  
g) Unscheduled visits may occur if subjects need to make a visit in between the scheduled visit dates due to an AE, difficulty c omplying with the trial protocol requirements, 
or a significant change in their disease state  
h) The informed consent form(s) must be signed prior to performing any protocol related procedures, including but not limited to  screening evaluations and alteration  of 
ongoing treatments unless medically justified  
i) All returned IMP tubes will be  weighed by [CONTACT_483612]  
j) Relevant prior/concomitant medication should be included from 6 months prior to Day 1 (baseline) until end of trial  
k) Relevant medical history must be recorded from the subjectâ€™s birth . In case medical history is incomplete at screening v isit, missing data will be retrieved at Day 1 
(baseline)  
l) BSA is assessed as a part of SCORAD  
m) Completion of the eDiary will be initiated at the latest 1 week prior to  Day 1 (baseline) . Compliance with the eDiary completion will be reviewed by [CONTACT_552299].  
n)  Only for subjects with a paid job.  
o) Subjects do not have to be fasting for safety laboratory samples  
p) Subjects with high risk  of latent tuberculosis (e.g. prior residence in or travel to countries with high prevalence of tuberculosis, close contact [CONTACT_29881] a person with active 
tuberculosis, or a history of active or latent tuberculosis where an adequate course of treatment cannot b e confirmed) must be tested  
q) For women of childbearing potential, a serum pregnancy test must be performed at the screening visit, and a urine pregnancy t est at Day 1 (baseline), Weeks 4 and 8 (end of 
treatment)  
r) If a subject reports  an AE , it is up to the i nvestigatorâ€™s discretion to perform an unscheduled visit  
s) Collection of 1 PK plasma sample 2 â€“6 hours after the morning application of IMP . Plasma sample should be collected from a non -treated area.  
t) The skin biopsy sampling  and the recommended photography scheduled at Day 1 (baseline) must be obtained prior to the first IMP application. This should be done both on 
lesional and corresponding non -lesional skin if possible  
u) The skin biopsy sampling scheduled at Week 1  and Week 8 should be done on lesional skin only 
v) The skin biopsy schedul ed at Week 8 will be obtained 2 â€“[ADDRESS_725864] to be obtained  

Trial ID: LP0133 -1275  Date: 22-Aug-2019  Version: 3.[ADDRESS_725865] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
w) An end of  trial form must be completed for all subjects, including subjects who discontinue IMP treatment prematurely or withdraw from the trial, at their last trial visit  (the 
early termination visit, the safety follow -up visit, or the primary endpoint visit, whic hever comes last)  
Abbreviations: ADSD, atopic dermatitis symptom diary; AE, adverse event; CMO, contract manufacturing organisation; DLQI, Dermatology Life Quality Index; ECG, 
electrocardiogram; EASI, Eczema Area and Severity Inde x; eDiary, electronic diar y; EQ -5D-5L, EuroQoL 5 Dimension Health Questionnaire 5 -Level; IgE, immunoglobulin E; IMP, 
investigational medicinal product; NRS, numeric rating scale; PGI-C, Patient Global Impression of Change; PGI -S, Patient Global Impression of Severity; PK, pharmacok inetics; 
POEM, Patient -Oriented Eczema Measure; SAE, serious adverse event; SCORAD, SCORing Atopic Dermatitis; SF -36: 36-item Short Form Health Survey ;  TSQM: Treatment 
Satisfaction Questionnaire for Medication; vIGA -AD, Validated Investigator Global Asses sment scale for  Atopic Dermatitis; WLQ, Work Limitation Questionnaire  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725866] up to 20% of children and up to 
10% of adults. AD is characterised by [CONTACT_312229], red, swollen, cracked and weepi[INVESTIGATOR_007] l esions 
with crusting and scaling, and is associated with pruritus and susceptibility to bacterial and 
viral skin infections ( Silverberg & Hanifin 2013 , Hanifin & Reed 2007 , Bieber 2008 , 
Weidinger & Novak 2016 ). AD is also associated with a substantial patient burden that 
typi[INVESTIGATOR_552281] , sleep disturbance and reduction in work productivity 
(Kiebert et al. 2002 ). 
AD is characterised by [CONTACT_483605]2 pathway in the skin ( Bieber 2008 , Bao et al. 2013 ) 
and increased expression of Th2 cytokines such as IL -4, IL-5, IL -13, IL -2, IL -31, IL -33, and 
thymic stromal lymphopoietin  (Brunner et al. 2017 ; Czarnowicki et al. 2017 ; Ong 2014 ).  
In the immune milieu of AD, the enhanc ement of Th2 cell proliferation and their release of 
various cytokines via the JAK-STAT pathway is likely the critical factor for the inflammatory 
responses in AD. This Th2 immune milieu triggers epi[INVESTIGATOR_552282], pro -inflammat ory cytokines, and angiogenic factors that participate in AD 
pathophysiology. Similarly, this Th2 immune upregulation could then lead to B cell 
maturation and plasma cell differentiation, result ing in hyper secretion of IgE. IgE binding to 
skin mast cells c auses histamine release, which further exacerbates AD. Moreover, IL -5 
released from this Th2 milieu could activate eosinophils that are attracted to the skin by [CONTACT_552300],  potentially  worsening the AD condition. In addition, by [CONTACT_552301] -31, an 
inducer of pruritus, AD becomes increasingly intensified ( Bao et al. 2013 ).  
5.[ADDRESS_725867]  
Delgocitinib , recently assigned as the international non -proprietary name (INN) for LEO 
124249,  is a pan -JAK inhibitor, which blocks various cytokine signalling pathways, and 
widely suppresses the activation of immune and inflammatory cells such as T  cells, B cells, 
mast cells, and monocytes activated by [CONTACT_552302].  
JAK is a family of i ntracellular tyrosine kinases consisting of 4 members, JAK1, JAK2, 
JAK3, and Tyk2, which can associate directly to the intra cellular part of various cytokine 
receptors in various combinations ( Pesu et al. 2005 , Murray 2007 ). After a cytokine binds to 
its cognate receptor, the relevant JAK members are autophosphorylated, which allow s them to 
phosphorylate one or more STAT protein (STAT1, STAT2, STAT3, STAT4, STAT5A/B, and 
STAT6). The phosphorylated ST AT proteins are in turn translocated to the nucleus where they 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725868] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
initiate transcription leading to promotion of growth and activation of a variety of cells. The 
JAK family is thus essential for cytokines involved in the pathogenesis of various diseases 
with an immune -inflammatory component to exhibit their physiological activity. The immune 
mechanisms in AD are mostly driven by T c ells, and JAK inhibitors inhibi t signal 
transduction of many T cell-released cytokines.  
In non -clinical studies, delgocitinib blocked JAK family members with IC50 values ranging 
from 2â€“[ADDRESS_725869] dermatitis, where 
T cells activated by [CONTACT_552303] -dependent cytokines were involved in the pathogenesis. 
Furthermore, delgocitinib improved the impaired skin barrier function, and reduced IL -31-
induced scr atching in mice. In a study by [CONTACT_552304] ., it was shown that IL -4 and IL -13 
downregulated genes involved in keratinocyte differentiation, that STAT3 and STAT6 are 
involved in keratinocyte differentiation and chemokine production, respectively, and that 
topi[INVESTIGATOR_552283]3 activation and improved skin barrier 
function ( Amano et al. 2015 ). 
So far, the clinical development programme for delgocitinib  has been based on an ointment 
formulation. No cl inical trials with the cream formulation have been conducted to date . 
A total of 7 clinical trials covering different patient populations/indications have been 
conducted with delgocitinib  ointment: Three phase [ADDRESS_725870] of delgocitinib , formulated as an ointment , 
compared to delgocitinib  ointment vehicle in terms of the percent change in the modified 
EASI score (excluding head/neck region) from baseline to e nd of the [ADDRESS_725871] clinical trial to investigate the cream formulation in 
subjects with AD.  

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

7KHSXUSRVHRIWKHWULDOLVWRHVWDEOLVKDGRVH UHVSRQVHVLJQDODQGWRHYDOXDWHWKH HIILFDF\DQG
VDIHW\RIGHOJRFLWLQLE DQGPJ JIRUPXODWHGDVDFUH DPIRUWRSLFDOXVHLQWKH
WUHDWPHQWRIVXEM HFWVZLWKPLOGWRVHYHUH$' 7KHUHVXOWVIURPWKLVWULDOZLOOVXSSRUW IXUWKHU
GHYHORSPHQWLQSKD VHZLWKUHJDUGVWR HJGRVHVHOHFWLRQDQGWUHDWPHQWGXUDWLRQ 
7KHUHLVDFOHDUXQPHWQHHGIRU QHZWUHDWPHQWRSWLRQVLQWKHWU HDWPHQWRISDWLHQW VVXIIHULQJ
IURP$'%DVHGRQWKHFXUUHQWO\DYDLODEOHQRQ FOLQLFDODQGFOLQLFDOGDW DGHOJRFLWLQLE KDVWKH
SRWHQWLDOWREHFRPHDQRYHOORFDO DFWLQJDQWL LQIOD[COMPANY_003]WRU\DQGLPPXQRVXSSUHVVLYHDJHQW
ZLWKVNLQEDUULHULPSURYLQJSURSHUWLHV $PDQRHWDO IRUWRSLFDOXVHLQ$' 7KHUHLVD
UHDVRQDEOHH[SHFWDWLRQ WKDWGHOJRFLWLQLE LQDFUHDPIRUPXODWLRQZLOOSURY HWREHDQHIIHFWLYH
DQGZHOOWROHUDWHGWUHDWPHQWEDVHGRQWKHPH FKDQLVPRIDFWLRQDQGWKHUH E\IDFLOLWDWHWKH
HYHU\GD\OLYHVRIDIIHFWHGSDWLHQWV 
'HOJRFLWLQLE ZDVRULJLQDOO\GHYHORSHGDVDQRLQWPHQWDQG WKLVIRUPXODWLRQKDVEHHQ XVHGLQ
DOOFOLQLFDOWULDOVSHUIRUPHGVRIDU ZLWKWRSLFDODGPLQLVWUDWLRQ $FUHDPIRUPXODWLRQKDVQRZ
EHHQGHYHORSHGIRUIXUWKHUF OLQLFDOGHYHORSPHQWZLWKWKHPDLQS XUSRVHRIRSWLPLVLQJ WKHVNLQ
GHOLYHU\DQGLQFUHDVHSDWLHQW IULHQGOLQHVV'HOJRFLWLQLE FUHDPFRQWDLQVDUHODWLYHO\ORZ
DPRXQWRIOLSLGZKLFKIDFLOLWDWHVIDVW DEVRUSWLRQLQWRWKHVNLQDQGOHDYLQJWKHVNLQOHVVJUHDV\
IROORZLQJWUHDWPHQWUHODWLYHWRWKHRLQWPHQW 
-XVWLILFDWLRQIRUGRVH 











7KLVGRVH UDQJLQJWULDOZLOOLQYHVWLJDWHWKH PD[LPXPUDQJHDYDLODEOHZLWK IRUPXODWLRQ
VWUHQJWKVRIG HOJRFLWLQLEFUHDPUDQJLQJIURPWRPJJ7KHKLJKHVWVWUHQJ WKPJJKDV
EHHQVHOHFWHGDVWKLVLVWKHKLJKH VWSRVVLEOHVWUHQJWKDWWKLV VWDJHRIWKHSKDUPDFHXWLFDO
GHYHORSPHQW7KHORZ HVWVWUHQJWKRIPJJ KDVEHHQVHOHFWHGLQ RUGHUWRFRYHUDODUJ HUDQJHCCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725872] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
of potential strengths. The formulation strengths are distributed equidistant ly on the natural 
logarithmic scale (rounded to whole numbers 1, 3, 8, and 20 mg/g).  
5.[ADDRESS_725873] their origins in 
the D eclaration of Helsinki, the ICH -GCP guidelines, in compliance with the approved 
protocol, and applicable regulatory requirements.  
Risks associated with treatment in this clinical trial (risks of experiencing signifi cant adverse 
reactions associated with dermal or systemic exposure to delgocitinib ) are considered 
minimal.  
The trial design chosen for this efficacy and safety trial with delgocitinib  cream is regarded as 
ethically justified and adherent with ethical requirements. The efficacy and safety of 
delgocitinib  cream will be evaluated in adults suffering from mild to severe AD who may 
benefit from treatment in the trial. Pregnant or breastfeed ing women and women trying to 
become pregnant will not be enrolled in the trial. Women of childbearing potential must agree 
to use a highly effective method of contraception to prevent pregnancy during the trial.  
Trial subjects will be informed at the scre ening visit that trial procedures prior to baseline 
(Day 1) may warrant an alteration o f their ongoing concomitant treatments. As applicable for 
the entire trial, the subjects will be instructed to contact [CONTACT_552305] . 
In accordance with the current version of the ICH -GCP guidelines, qualified medical 
personnel employed by [CONTACT_483609] -related medical 
questions. Medical monitoring will be performed throughout the trial. Safety data w ill be 
reviewed regularly by [CONTACT_552306].  
5.6 Benefit/ risk assessment  
There is an unmet medical need for new topi[INVESTIGATOR_552284]/or safety . 
No important identified risks have been documented during the overall non -clinical and 
clinical development of delgocitinib  to date. A detailed overview of non -clinical and clinical 
data on delgocitinib  is available in the current Investigatorâ€™s Brochure.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725874]. The size of the skin biopsies should not 
necessitate suturing, but suturing can b e performed at the investigatorâ€™s discretion. The risk 
associated with a skin biopsy, including secondary infection, is considered low.  
Altogether, the risks associated with participating in this clinical trial are considered very low 
and outweighed by [CONTACT_73292] a potential future treatment option for AD. There is an 
opportunity for a positive treatment effect for the subjects participating in this clinical trial 
based on the currently available clinical data.  
  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725875] of delgocitinib 
on S. aureus  colonisation of the skin, 
skin microbiome, and skin 
inflammation . ï‚· Change in SF -36 from baseline to Week 8 . 
 
Efficacy over time  
ï‚· vIGA-AD TS at each scheduled assessment until Week 
6. 
ï‚· EASI75 at each scheduled assessment until Week 6 . 
ï‚· Change in SCORAD from baseline  to each scheduled 
assessment until Week 6 . 
ï‚· Change from baseline to ea ch week from  Week 1 to 
Week 7  in ADSD  (weekly average for each individual 
symptom) . 
o Reduction of wor st pruritus (weekly average) of â‰¥[ADDRESS_725876] pruritus 
(weekly average)  â‰¥4.  
ï‚· Change from baseline to ea ch week from  Week 1 to 
Week 7  in Eczema -related Sleep NRS  (weekly 
average) . 
ï‚· Change in DLQI score from baseline to each scheduled 
assessment until Week 6 . 
ï‚· Reduction in DLQI of â‰¥4 points from baseline to each 
scheduled assessment until Week  6 among subjects 
with baseline DLQI â‰¥4. 
 
 
Biomarkers  
ï‚· Change in S. aureus colonisation from baseline to 
Week 8 . 
ï‚· Change in microbiome composition from baseline to 
Week 8 . 
ï‚· Change in expression of genes involved in AD 
pathogenesis in skin biopsies from baseline to Week 
1. 
ï‚· Change in expression of genes involved in AD 
pathogenesis in skin biopsies from baseline to Week 
8. 
Abbreviations: ADSD, atopic dermatitis symptom diary; AE, adverse event; DLQI, Dermatology Life Quality Index; EASI, 
Eczema Area and Severity Index; EQ -5D-5L, EuroQoL 5 Dimension Health Questionnaire 5 -Level; NRS, numeric rating 
scale; POEM, Patient -Oriented Eczema Measure; SAE, serious adverse event; SCORAD, SCORing Atopic Dermatitis; SF -
36: 36 -item Short Form Health Survey;  TSQM: Treatment Satisfaction Questionnaire for Medication; vIGA -AD, Validated 
Investigator Global Assessment scale for  Atopic Dermatitis; WLQ, Work Limitation Questionnaire  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725877] s of a screen ing period , a treatment period and a follow -up period . 
Screening period - between 2  and 4  weeks  prior to baseline visit (Day 1)  
The screening p eriod has a minimum duration of 2 week s and a maximum duration of 4 
weeks.  
At the screening visit, the subjects â€™ eligibility to enter the trial will be checked . Trial-specific 
measurements will be performed as outlined in Section  11. 
The subjects will receive training in completion of an  eDiary  at the screening visit  and will be 
given a n electronic  device to record certain PROs. Furthermore, to complete training of the 
eDiary and as an opportunity to fill out PROs before the treatment period, subjects will be 
asked to complete PROs at the  screening visit. Completion  of the eDiary will be initiated  at 
the latest  1 week prio r to the baseline visit (Day  1). 
All subjects must use an emollient twice daily (or more, as needed) for at least 14 days before 
Day 1 ; this background treatment should p referably be an additive free, basic bland emollient. 
After randomisation  on Day [ADDRESS_725878]  not be used concomitantly with delgocitinib  
cream  or delgocitinib  cream vehicle on lesional skin. Subjects may however continue to use 
their background emollient treatment on non -lesional skin throughout the trial (including 
safety follow -up). 
Treatment period - 8 weeks  
At baseline (Day 1), subjects â€™ eligibility to enter the trial will be confirmed and , if still 
eligible , subjects can be randomised 1:1:1:1:1 to one of the following 5 treatment groups in a 
1:1:1:1:1 ratio : delgocitinib  cream 1, 3, 8, 20 mg/g or delgocitinib  cream vehicle.  
The subjects will apply the IMP ( delgocitinib  cream 1, 3, 8, or 20 mg/g or delgocitinib  cream 
vehicle) twice daily for [ADDRESS_725879] application of the IMP will occur at the trial site on 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725880] been carried out. The subsequent  IMP applications 
will be performed by [CONTACT_339697].  
During the 8 -week treatment period, the subjects will return to the trial sites for the visits 
scheduled at Weeks 1, 2, 4, 6, and 8. On Day 4, a member of trial site personnel will call the 
subjects to ask them a non -leading question about AEs e.g. â€œHow ha ve you felt since I saw 
you last? â€, and to inquire about compliance with treatment and eDiary completion. The last 
IMP application will occur at the subjects â€™ home before the subjects attend the visit scheduled 
at Week 8. Efficacy and safety assessments du ring the treatment period will be performed as 
described in Section 11. 
Follow -up period - [ADDRESS_725881] completed the entire trial. For subjects who disc ontinue trial treatment 
prematurely or withdraw from the trial, please refer to Section 10.3. 
7.2 Number of subjects needed  
This trial will be conducted at approximat ely 25  sites in North America and Australia. The 
anticipated minimum number of randomised subjects per trial site is 6 and the maximum 
number of subjects per trial site is 30.  
Assuming a screening failure rate of approximately 25%, approximately 334 subje cts will be 
screened and approximately 250 subjects will be randomly assigned to trial treatment (50 
subjects in each of the 5 treatment group s: delgocitinib  cream 1, 3, 8, and 20 mg/g and 
delgocitinib  cream vehicle ). The statistical power considerations f or this sample size are 
described in Section 14.1. 
The randomisation is stratified by [CONTACT_552296]-AD (vIGA-AD score 
of 2 (mild), 3 (moderate), or 4 (severe)) and region (North America and Australia).  
7.[ADDRESS_725882] completed all periods of the 
trial (i.e. screening, treatment and the safet y follow -up). 
The end of the trial is defined as the date of the last visit of the last subject in the trial 
globally . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725883] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Final collection of data for the primary endpoint occurs at Week 8. 
7.4 Software  
CDISC  controlled terminology version 30 -Mar-2018  or newer was used for definition of 
controlled terminology used throughout this  protocol and will be used for statistical 
programming and output. SDTM version 1.4 will be used for data tabulations and SDTM 
Implementation  Guide version 3.2 will be adhered to. 
Dose -response modelling  will be done using the package DoseFinding  implemented in R 
statistical software version 3. 5.0. All other analysis will be performed using SASÂ® statistical 
software version 9.4.  
 
 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725884] â€™s eligibi lity for the clinical trial must  be verified according to the inclusion and 
exclusion criteria at visits specified in Panel 2. It will be recor ded in the eCRF if the subject 
has met all the inclusion criteria and none of the exclusion criteria.  
Any implementation of national requirements/law for the subject â€™s partic ipation in the clinical 
trial will be ensured and described in submission document ation to regulatory authorities and 
IRBs/IECs , as applicable.   
8.[ADDRESS_725885] fulfil all of the following criteria : 
1. Signed and dated informed consent has been obtained prior to any protoco l-related 
procedures . 
2. Age 18 years and above . 
3. Diagnosis of AD as defined by [CONTACT_552307] ( Hanifin & Rajka 
1980 , Appendix 6 ). 
4. History of AD for â‰¥1 year. 
5. AD involvement of 5 â€“50% treatable body surface area  at screening and at baseline  
(excluding scalp) . 
6. Disease severity graded as mild to severe according to vIGA -AD (i.e. vIGA -AD â‰¥2) at 
scree ning and baseline . 
7. Able and willing to follow trial procedures including application of IMP to all AD 
lesions . 
8. A woman  of childbearing potential* must use a highly effective** form of birth 
control throughout the trial and at least for [ADDRESS_725886]  application  of IMP.  
* A woman is defined as not being of childbearing potential if she is postmenopausal 
(at least 12  months with no menses without an alternative medical cause prior to 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725887] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
screening), or surgically sterile (hysterectomy, bilateral salpi[INVESTIGATOR_31639], or bilateral 
oophorectomy).  
**A highly effective method of birth control is defined as one which results in a low 
failure rate (less than 1% per year) such as bilateral tubal occlusion, intrauterine 
device, intrauterine hormone -releasing system, combi ned ( oestrogen  and progestogen 
containing) hormonal contraception associated with inhibition of ovulation (oral, 
intravaginal, transdermal), progestogen -only hormonal contraception associated with 
inhibition of ovulation (oral, injectable, implantable), se xual abstinence (when this is 
in line with the preferred and usual life style of the subject), vasectomised partner 
(given that the subject is monogamous).  
8.[ADDRESS_725888] not enter the trial if any of the following exclusion criteria are fulfilled:   
1. AD lesion(s) on scalp at screening and /or baseline . 
2. Active dermatologic conditions that may confound the diagnosis of AD or would 
interfere with assessment of treatment, such as scabies, cutaneous lymphoma, rosacea, 
urticaria, or psoriasis.  
3. Known active allergic or irritant contact [CONTACT_552308] . 
4. Use of tanning beds or phototherapy (NBUVB, UVB, UVA1 , PUV A ) within 4 weeks 
prior to baseline . 
5. Treatment with the following medications withi n 4 weeks prior to baseline : 
ï‚· Systemic immunosuppressive/immunomodulating drugs (e.g. methotrexate, 
cyclosporine, azathioprine, mycophenolate -mofetil, Janus kinase inhibitors, 
retinoids ). 
ï‚· Systemic corticosteroid s (excludes inhaled  or intranasal deliver y). 
ï‚· Three or more bleach baths duri ng any week within the 4 weeks . 
6. Treatment with the following medications within 2 weeks prior to baseline : 
ï‚· TCSs. 
ï‚· TCIs. 
ï‚· Topi[INVESTIGATOR_22732] -4 inhibitor s. 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725889] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
ï‚· Oral antibiotics.  
7. Change in systemic antihistamine therapy within [ADDRESS_725890] not start antihistamine treatment or change the current dosage regime 
within 2 weeks prior to baseline . 
8. Receipt of  live attenuated vaccines 4 weeks  prior to baseline .  
9. Receipt of blood products within 4 weeks prior to screening .  
10. Treatment with any marketed biological therapy or investigational biologic agents 
(including immunoglobulin, anti -IgE or dupi[INVESTIGATOR_12458]) . 
ï‚· Any cell -depleting agents including but not limited to rituximab: within 
6 months prior to baseline , or unti l lymphocyte count returns to normal, 
whichever is longer . 
ï‚· Other biologics: within 3  months or 5 half -lives, whichever is longer, prior to 
baseline . 
11. Treatment with any non -marketed drug substance (that is, an agent which has not yet 
been made available for  clinical use following registration) within the last [ADDRESS_725891] â€™s ability to participate in the trial. 
Clinically significant infections are defined as:  
ï‚· A syste mic infection . 
ï‚· A serious skin infection requiring parenteral (intravenous or intramuscular) 
antibiotics, antiviral, or antifungal medication . 
15. Tuberculosis requiring treatment within t he 12 months prior to screening  and/or 
subjects with a positive blood tes t for tuberculosis at screening*.  
* Subjects with high risk of latent tuberculosis (e.g. prior residence in or travel to 
countries with high prevalence of tuberculosis, close contact [CONTACT_4490] a person with active 
tuberculosis, or a history of active or latent tuberculosis where an adequate course of 
treatment cannot be confirmed) must be tested.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725892] taking antiretroviral medications as determined by 
[CONTACT_96749]/or subject â€™s verbal report . 
17. Major surgery within 8 weeks prior to screening, or planned in -patient surgery or 
hospi[INVESTIGATOR_421415] . 
18. History of cancer:  
ï‚· Subjects who have had basal cell carcinoma, localised squamous cell 
carcinoma of the skin or in situ carcinoma of the cervix are eligible provided 
that the subject is in remission and curative therapy was completed at least 
12 months prior to screening . 
ï‚· Subjects who have had other malignancies are eligible provided that the 
subject is in remission and curative therapy was completed at least 5 years 
prior to screening . 
19. Any disorder, including but not limited to, cardiovascular, gastrointestinal, hepatic, 
renal, neurological, musculoskeletal, infectious, endocrine, metabolic, haematological, 
immunological, psychiatric, or major physical impairment that is not stable, in the 
opi[INVESTIGATOR_871], and could:  
ï‚· Affect the safety of the subject throughout the  trial. 
ï‚· Influence the findings of the trial or their interpretations . 
ï‚· Impede the subject â€™s ability to complete the entire duration of trial . 
20. Any abnormal finding which may:  
ï‚· Put the subject at risk because of his/her participation in the trial . 
ï‚· Influence the results of the trial . 
ï‚· Influence the subject â€™s ability to comple te entire duration of the trial . 
The abnormal finding must be clinically significant and observed during the screening 
period. Examples include abnormal findings in physical examination, vi tal signs, 
ECG, haematology, clinical chemistry, or urinalysis.  
21. Positive HBsAg, HBsAb, HBcAb or anti-HCV  serology  at screening. Subjects with 
positive HBsAb may be randomised provided they are hepatitis B vaccinated and have 
negative HBsAg and HBcAb . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725893] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
22. Alanine aminotransferase or aspartate aminotransferase level â‰¥2.0 times the upper 
limit of normal range at screening . 
23. Known or suspected hypersensitivity to any component(s) of the IMP . 
24. Current participation in any other interventional clinical trial . 
25. Previous randomisation in this clinical trial . 
26. History of chronic alcohol or drug abuse within [ADDRESS_725894] 
identification  number (subject  ID) will be assigned by a central IRT system  and the screening 
evaluations to assess eligibility criteria  may begin . The subject ID will be used to identify the 
subject during the screening process and throughout trial participation, if ap plicable.  Subjects 
who have given written informed consent to participate in the trial and who have been 
assigned a subject  ID are considered â€˜screened â€™ subjects.  
The investigator will maintain a log of all consented subjects at the trial site  (subject 
identification list). This log  will include each subject â€™s identity, date of consent and 
corresponding subject ID so that any subject may be identified if required for any reason. The 
log must not be copi[INVESTIGATOR_121482].  In addition, the in vestigator will maintain a log of 
all subjects considered for screening, whether they have provided written informed consent  or 
not (screening log) . This log will be anonymous and will include the reason(s) for not entering 
the trial, if applicable, or the  allocated subject ID.  
Screening failures  
Screen ing failures are defined as subjects who consent to participate in the trial but are not 
subsequently randomly assigned to trial treatment. A minimal set of screen ing failure 
information is required to ensure  transparent reporting of screen ing failure subjects to meet 
the C ONSORT publishing requirements  (Schulz et al. 2010 ) and to respond to queries from 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725895] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
regulatory authorities. Individuals who do not meet the criteria for participation in the trial 
(screening failures) may not be re -screened . However, if the reason for screening failure is 
administrative e.g. delayed test results and not due to the subject failing to meet the eligibility 
criteria , re-screening may be permit ted. Individuals who are re -screened will get a new subject 
ID. 
The following data will be collected in the eCRF for screening failures:  
ï‚· Date of informed consent (s). 
ï‚· Demographics (date of birth , age, sex, ethnicity, race) . 
ï‚· Reason for screen ing failure:  
o Failure to meet eligibility criteria  (specify which) .  
o Withdrawal by [CONTACT_1130] . 
o Other (specification is required) . 
ï‚· Date of screen ing failure . 
ï‚· Any AEs and SAEs . 
 
In case of any SAEs, these must be followed -up as described in Section  13.7. 
  

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

7UHDWPHQWV 
7ULDOSURGXFWGHVFULSWLRQ 
'HOJRFLWLQLE LVDSDQ-$.LQKLELWRUZKLFKLVSUHVHQWHG LQWKLVWULDO DVDFUHDPIRUPXODWLRQ IRU
WRSLFDODSSOLFDWLRQ 3OHDVHUHIHUWR 3DQHOIRUIXUWKHUGHWDLOV 
3DQHO,GHQWLILFDWLRQRI ,03V
,QYHVWLJDWLRQDOPHGLFLQDO
SURGXFW)RUPXODWLRQ $FWLYHLQJUHGLHQWDQG
IRUPXODWLRQFRQFHQWUDWLRQ3DFN
VL]H6RXUFH
'HOJRFLWLQLEFUHDPPJJ &UHDP 'HOJRFLWLQLEFUHDPPJJ J 

'HOJRFLWLQLEFUHDPPJJ &UHDP 'HOJRFLWLQLEFUHDPPJJ J 

'HOJRFLWLQLEFUHDPPJJ &UHDP 'HOJRFLWLQLEFUHDPPJJ J 

'HOJRFLWLQLEFUHDPPJJ &UHDP 'HOJRFLWLQLEFUHDPPJJ J 

'HOJRFLWLQLEFUHDPYHKLFOH &UHDP 9HKLFOH J 


$GPLQLVWUDWLRQRI ,03
7KH,03 GHOJRFLWLQLE FUHDPRUPJJRU GHOJRFLWLQLE FUHDPYHKLFOHZLOOEH
DGPLQLVWHUHGDVDWZLFHGDLO\ WRSLFDODSSOLFDWLRQIRUZHHNV7KHDSSOLFDWLRQVZLOOEH
SHUIRUPHGDSSUR[LP DWHO\KRXUVDSDUW ,QVWUXFWLRQVIRUXVHZLOOEHSURYLGHG 
$WKLQOD\H URI,03FRYHULQJWKHDIIHFWHGDUHDVZLOOEHDSSOLHG DFFRUGLQJWRWKHLQVWUXFWLRQV
IRUXVH7KHPD[LPXP DPRXQWRI,03WREH XVHGGHSHQGVRQWKHVL]H RIWKHDIIHFWHG %6$
2QHWXEHRIJGHOJRFLWLQLEFUHD PLVFRQVLGHUHGDGHTXDWHIRU RQHDSSOLFDWLRQIRU VXEMHFWV
ZLWK%6$RI 
7KHILUVWDSSOLFDWLRQRIWKH,03 ZLOORFFXUDWWKHWULDOVLWH 3ULRUWRWKHILUVW,03DSSOLFDWLRQ
WKHVXEMHFWZLOOEHLQVWUXF WHGKRZPXFKFUHDPWRDSSO\ DQGZKLFKDUHDV DUHWREHWUHDWHG
2QO\WKHDIIHFWHGDUHDVRQWKHVNLQ H[FOXGLQJ VFDOSZLOOEHWUHDWHG,IQHZOHVLRQVRFFXURQCCI
CCI
CCI
CCI
CCI
Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725896] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
initially untreated area(s) of the skin, these new lesions will be treated with IMP as well  
except if they occur  on scalp . Subjects should be advised to contact  [CONTACT_552309] . 
The IMP application on initia lly affected areas  and new lesions will continue until Week [ADDRESS_725897] â€™s home before the subject attends the visit 
scheduled at Week 8.      
The IMP will be dispensed by [CONTACT_552310] 4. The 
IRT will assign the required kit number(s) for each subject at each dispensing visit.  
The investigator will use clinical judg ement  to treat any symptoms connected with an 
overdose.  
9.[ADDRESS_725898] been found to meet  all the inclusion criteria and not to fulfil  any of the 
exclusion criteria will be randomised centrally at baseline (Day 1)  to receive treatment with 
either delgocitinib  cream (1, 3, 8 , or 20  mg/g ) or delgocitinib  cream vehicle . The treatment 
assignment  will occur on the basis of a co mputer -generated randomisation scheme in a 
1:1:1:1:[ADDRESS_725899] â€™s safety. In many cases, IMP discontinuation and 
knowledge of the possible treatment assignment are sufficient to treat a trial subject who 
presents with an emergency condition. An emergency unblinding request can be made by [CONTACT_4520], health care professi onals who are not members of the trial staff , or authorised 
LEO personnel.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725900] â€™s treatment in th e 
IRT. For a requester who is not a member of the trial staff and who does not have access to the 
IRT (e.g. a physician at an emergency room ), a local contact [CONTACT_73298] (see Appendix 3B) to be used if the 
investigator or delegated site staff cannot be reached . The requester will provide the trial ID 
and subject  ID to the emergency unblinding CRO who will immediately reveal the subject â€™s 
treatment allocation.  
The emergency unblinding CRO will clarify that the requester requires immediate unblinding 
without further medical consultation. Should the requester wish to discuss whether unb linding 
is necessary, the  emergency  unblinding CRO will provide the requester with the LEO 24/[ADDRESS_725901] which will be diverted to the medical cover.  
9.4 Background treatment  (emollients)  
All subjects must use an emollient twice daily (or more, as needed) for a t least 14 days before 
randomisation; the background treatment should preferably be an additive free, basic bland 
emollient. Af ter randomisation emollients must  not be used concomitantly with IMP on 
lesional skin. Subjects are however  allowed to  continue t heir background emollient treatment 
on non -lesional skin throughout the trial (including safety follow -up). 
9.5 Rescue treatment  
If medically necessary (i.e. to control intolerable AD symptoms), rescue medication for AD 
may be provided to trial subjects at the discretion of the investigator. The i nvestigators should 
make every attempt to conduct efficacy and safety assessments ( for example  disease severity 
scores , safety laboratory assessments ) immediately before administering any rescue treatment.  
If rescue medication is initiated, the s ubject must stop  treatment with IMP immediately and 
must not  restart treatment with IMP.  It must be stated in the eCRF that the subject receives 
rescue medication.  
9.[ADDRESS_725902]  receiv es from 6 months prior to  baseline (if 
relevant)  through the safety follow -up period  must be recorded in the subject â€™s medical record 
and the eCRF along with  details such as : 
ï‚· Medication name . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725903] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
ï‚· Indication . 
ï‚· Start and stop date of administration  (it will also be recorded if the medication 
is ongoing ). 
ï‚· Dosage information , including dose , unit, and frequency . 
ï‚· Route of administration . 
ï‚· For topi[INVESTIGATOR_35786], the b ody location must be recorded: it must be recorded 
if the treatment is within 5 cm (approximately 2 inches) of the treatment area . 
Similarly, any concurrent procedure must also be recorded  in the subject â€™s medical record and 
the eCRF.  The following details will be recorded:  
ï‚· Procedure . 
ï‚· Body location .   
ï‚· Diagnosis . 
ï‚· Start and stop date  (it will also be recorded if the procedure is ongoing ).  
ï‚· For topi[INVESTIGATOR_12969], it must also be recorded if the procedure is inside the 
treatment area . 
Investigators may prescribe concomitant medications or treatments to provide adequate 
supportive care as deemed necessary, except fo r medications listed in Section  9.7. Use of 
emollients is described in Section 9.4. 
No concomitant medication is allowed on lesional s kin. On non -lesional skin, background 
treatment, preferably an additive  free basic bland emollient, is allowed.  
9.[ADDRESS_725904] stop treatment with IMP 
immediately (see Section 9.5). 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725905] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Panel 5: Prohibited medication  and procedures  
Medication  Prohibited from  Prohibited to  
Systemic treatment with immunosuppressive  
drugs (e.g. methotrex ate, cyclosporine, 
mycophenolate -mofetil, azathioprine ), 
immunomodulating drugs (e.g.  JAK 
inhibitors ), retinoids  (e.g. alitretinoin ) or 
corticosteroids ( inhaled or intra -nasal steroids 
corresponding to up to 1 mg pre dnisone for 
asthma or rhinitis may be used ) 4 weeks prior to baseline  End of trial  
Use of tanning beds , phototherapy (e.g. PUVA 
or UVB therapy ) or bleach baths  4 weeks prior to baseline  End of trial  
Live attenuated vaccines  4 weeks  prior to baseline  End of trial  
 
TCSs, TCIs or topi[INVESTIGATOR_22732] -4 inhibitors  2 weeks prior to baseline  End of trial  
Change in systemic antihistamine therapy  2 weeks prior to baseline  End of trial  
Blood products  4 weeks prior to screening  End of trial  
Any marketed biological therapy or 
investigational biologic agents (including 
immunoglobulin, anti -IgE, or dupi[INVESTIGATOR_12458]):   
 
  
ï‚· Any cell -depleting agents includi ng 
but not limited to rituximab  
 6 months prior to baseline or 
until lymphocyte count returns 
to normal, whichever is 
longer.  End of trial  
ï‚· Other biologics  3 months or 5 half -lives, 
whichever i s longer, prior to 
baseline  End of trial  
Any no n-marketed drug substance (i.e.  an 
agent which has not yet been made available 
for clinical use following registration).  [ADDRESS_725906]  End of trial  
Topi[INVESTIGATOR_35786] ( e.g. drug, non -drug, wet 
wraps ) on lesional skin other than the use of 
IMP. Baseline  End of trial  
 
9.8 Treatment logistics and a ccountability  
9.8.1 Labelling and p ackaging of trial products  
The IMP s will be packaged in individually numbered kits . 
Primary and secondary packaging materials  will be individually labelled.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725907] be stored at 2â€“8Â°C (36â€“46Â°F) at the trial site. Do not freeze. The temperature 
during storage shou ld be monitored b y a calibrated , stationary, and continuously electronic 
recording system with alarm and back -up of data. If no alarm is triggered, a log must be 
printed, reviewed, signed and dated each month. If the alarm  is triggered , the log must be 
immediately printed, reviewed, signed and dated, and appropriate follow up action will be 
taken in accordance with the trial product  handling manual .  
A temperature log from the recording system must be kept at the trial site to document th e 
storage within the right temperature interval. Storage facilities should be chec ked at least 
every working day.  
Storage  of the IMPs may be delegated, e.g. to a hospi[INVESTIGATOR_4601], as locally applicable.  
In the situations listed below, site staff should no t use the affected IMPs and should 
immediately contact [CONTACT_547713]:  
ï‚· Temperature excursion upon receipt or during storage at the trial site . 
ï‚· Damaged kit  upon receipt . 
Damaged IMP should be documented in the IRT  and reported as a product complaint to 
Global Pharmacovigilance, LEO (see Section 9.10). Damaged IMP may not be used.   
Further details regarding s torage (including handling of temperature excursions upon receipt 
or during storage at the trial site) and handling of damaged IMPs (including kits damaged 
upon receipt) are provided in the trial product handling manual.  
9.8.3 Drug accountability  
IMP accountabil ity 
The investigator is fully responsible for the IMPs at the trial site and for maintaining adequate 
control of the IMPs and for documenting all transactions with them.  
Dispensing of IMPs may be delegated, e.g. to a hospi[INVESTIGATOR_4601], as locally applicable.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725908] 
dispensing of the IMP. Drug accountability information will be entered in the IRT, where also 
inven tory status of all IMP at the trial site will be maintained . 
The subjects will return used, and unused  IMP ( including packaging materia l) at the visits 
specified in the schedule of trial procedures (Section 4). 
Returned trial product s (used, and unused IMP [ including packaging material ]) can be stored 
at room temperature and mus t be stored separately from non -allocated trial product s. 
All IMPs (including packing material) supplied by [CONTACT_552311] . Prior to return, the IMP must be fully accounted for 
by [CONTACT_548862] s.  
All tubes  returned to the CMO will be weighed to determine the amount of IMP used.  
Reporting in eCRF  
The kit /tube  number, date of IMP dispensation and return, and number of tubes dispensed and 
returned will be recorded in the eCRF.  
9.8.[ADDRESS_725909] be applied and what amount of IMP to be used 
per application.      
At the phone call scheduled on Day 4 and at eac h visit scheduled in the treatment period (see 
Section 4), the subject will be asked if they have used the IMP as prescribed. If a subject is 
found to be non -comp liant, the investigator must  remind the subject of the importance of 
following the instructions given, including applying the IMP as prescribed. Compliance or 
non-compliance, i.e.  number of missed IMP applications and the reason for it, must be 
recorded in the eCRF.  
9.8.[ADDRESS_725910] destruction  
Used and unused IMP s will be destroyed by [CONTACT_552312]/or local requirements.  

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

3URYLVLRQIRUVXEMHFWFDUHIROOR ZLQJWULDOFRPSOHWLRQ 
,QRUGHUWRHQVXUHDSSURSULD WHWUHDWPHQWRIWKHVXEMHFWVDIWHU WKH\KDYHFRPSOHWHGWKHWULDOWKH
VXEMHFWVZLOOEHWUHDWHGDWWKHLQYHVWLJDWRU Â¶VGLVFUHWLRQRUUHIHUUHGWRRWKHUSK\VLFLDQV
DFFRUGLQJWRVWDQGDUGSUDFWLFH 
5HSRUWLQJ SURGXFWFRPSODLQWV 
$Q\GHIHFWVRULVVXHVZLWKWKH,03 HJVWUDQJHFRORXURUFRQVLVWHQF \LQDGHTXDWHODEHOOLQJ
PXVWEHUHSRUWHG WR*OREDO3KDUPDFRYLJLODQFHDW /(2RQWKH WULDOVSHFLILFSDSHU FRPSODLQW
IRUPZLWKLQGD\VRIILUVWNQRZOHGJH 
&ULWLFDOFRPSODLQWVGHILQHGDVDQ\ GHIHFWRULVVXHWKDWKDVRUSRWHQWLDOO\FRXOGKDYHD VHULRXV
LPSDFWIRUWKHVXEMHFW HJ6$(PXVWEHUHSRUWHGWR*OREDO3KDUPDF RYLJLODQFH/(2ZLWKLQ
KRXUV
&RPSODLQWIRUPVVKRXOGFRQWDLQD GHWDLOHGGHVFULSWLRQRI WKHGHIHFW RULVVXHLQFOXGLQJ
ZKHWKHULWOHGWRDQ$(6$(VZKLF KRFFXUGXHWRDGHIHFWRU LVVXHZLWKWKH,03 ZLOOEH
UHSRUWHGE\WKHLQYHVWLJDWRUDVGHVFULEHGLQ 6HFWLRQVDQG
5HIHUWRWKH WULDOSURGXFW KDQGOLQJPDQXDOIRULQIRUPDWLRQRQKRZWRXSGDWHWKHNLWVWDWXVLQ
WKH,57
'XULQJWKHLQYHVWLJD WLRQRIWKHSURGXFWFRPSODLQWWKH ,03PXVWEHVWRUHGDWODEHOOHG
FRQGLWLRQVXQOHVVRWKHUZLVHLQVWUXFWHGWKHWULDOVLWHZLOOEH QRWLILHGZKHWKHUWKH ,03QHHGVWR
EHUHWXUQHGIRUIXUWKHULQYHVWLJD WLRQRUPD\EHGHVWUR\HG 
*OREDO3KDUPDFRYLJLODQFH/(2 FRQWDFWLQIRUPDWLRQIRUUHSRUWLQJ SURGXFWFRPSODLQWV 
)D[QXPEHU 
(PDLODGGUHVV 
'LVFRQWLQXDWLRQDQGZ LWKGUDZDO 
*HQHUDOSULQFLSOHV 
$VXEMHFWPD \ZLWKGUDZIURPWKHWULDOLH ZLWKGUDZIURPWUHDWPHQWDQGSURWRFRO GHILQHG
LQWHUYHQWLRQVRUSHUPDQHQWO\GL VFRQWLQXHWULDOWUHDWPHQW LHVWRSWUHDWPHQWRQO\EXWDJUHHWR
FRQWLQXHGSURWRFRO GHILQHGLQWHUYHQWLRQVDWDQ \WLPHSULRUWRILUVWGRVHRUGXUL QJWKH
WUHDWPHQWSHULRGLIWKHVXEMHFWW KHLQYHVWLJDWRURU/(2FRQV LGHUVWKDWLWLVQRWLQWKH
VXEMHFWÂ¶VEHVWLQWHUHVWWRFRQWLQXH CCI
CCI
Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725911] withdraws from the trial, he/she may request destruction of any samples taken and 
not tested, and the investigator must document this in the subject â€™s source documentation.  
Subjects who withdraw from the trial and subjects who discontinue tri al treatment will not be 
replaced.  
Data to be recorded in the eCRF  
The primary reason for withdrawal from the trial and  discontinuation of IMP must be 
recorded in the medical records and on the end of trial form in the eCRF where the following 
options are available:  
ï‚· Lack of efficacy . 
ï‚· Adverse event . 
ï‚· Withdrawal by [CONTACT_1130] . 
ï‚· Lost to follow -up. 
ï‚· Pregnancy . 
ï‚· Death . 
ï‚· Other . 
If â€˜adverse event â€™ or â€˜other â€™ is selected, a specification must be provided in the eCRF  with a 
clear link to the specific AE if applicable.  
10.2 IMP discontinuation rules  
10.2.1  Reasons for discontinuation of IMP  
Subjects will disco ntinue  IMP in the event of:  
ï‚· An AE that, in the opi[INVESTIGATOR_26335] â€™s medical expert, 
contraindicates further dosing . 
ï‚· Evidence of pregnancy . 
ï‚· Initiation of rescue medication . 
ï‚· Clinically important laboratory abnormalities:  
o Alanine aminotransferase and/or aspartate aminotransferase 
values >3Ã—ULN with total bilirubin >2Ã—ULN (unless elevated 
bilirubin is related to Gilbert -Meulengracht Syndrome).  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725912] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
o Confirmed aspartate aminotransferase  and/or alanine 
aminotransferase  >5Ã—ULN (for more than 2 weeks).  
ï‚· Any infection that is opportunistic, such as active tuberculosis and other 
infections whose nature or course may suggest an immuno -compromised 
status.  
ï‚· Lymphopenia ( lymphocyte s <0.5x109/l; grade 3 according to CTCAE v5.0) 
confirmed by [CONTACT_260055] [ADDRESS_725913] trial visit (the early termination visit, 
the safety follow -up visit, or the primary endpoint visit, whichever comes last).  
Withdrawal from trial  
Subjects who withdraw from the trial must  attend an early termination visit as soon as 
possible after last administration of IMP (see th e schedule of trial procedures [ Section  4] for 
data to be collected at an early termination visit).  The investigator will review any AEs which 
will be followed -up according to Section  13.7, if the subject agrees.  
Discontinuation of IMP  
Subjects who discontinue IMP for any reason prior to Week [ADDRESS_725914] application  of IMP and return to the trial site for 
2 addit ional visits as indicated below. S ee the schedule of trial procedures (Section  4) for data 
to be collected a t these visits .  
Subjects who discontinue IMP prior to Week  8 will be asked to attend:  
ï‚· Early termination visit  (as soon as possible after the last IMP application) . 
ï‚· Safety follow -up visit ([ADDRESS_725915] application of IMP) . 
ï‚· Primary endpoint visit ([ADDRESS_725916] IMP application) . 
10.[ADDRESS_725917] to follow -up if he/she  repeatedly fail s to return for scheduled 
visits and if the trial site is not able to get in con tact with the subject.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725918] fails to return to the trial site for a required 
visit:  
ï‚· The trial site must attempt to contact [CONTACT_552313].  
ï‚· Before a subject is deemed lost to follow -up, the investigator or designee must 
make every effort to regain contact [CONTACT_1155].  Should the subject 
continue to be unreachable, they will be considered to have withdrawn from 
the trial with a prima ry reason of lost to follow -up. 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725919] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
11 Trial assessments  and procedures  
11.1 Overview  
Evaluations to be done at each visit are shown in the schedule of trial procedures in Section  4. 
Refer to Section  7.1 for further details on the trial design.  
Assessments and procedures at each trial visit should be performed in the following order  as 
shown in Panel 6: 
Panel 6: Sequence of assessments  
 
* Blood sampling for PK, skin swabs, skin biopsies (optional) and photography of biopsied 
areas  (recommended ). 
Subjects participating in the trial will be under careful supervision of a principal investigator 
[INVESTIGATOR_73232]  a dermatologist or allergist . Inves tigators must be experienced in treating AD 
and have documented experience and/or training in use of the assessments required by [CONTACT_33230] -reported outcomes
At the screening visit, subject's eligibility to enter the trial has to be 
confirmed before the PROs can be completed 
Efficacy assessments by [CONTACT_552314]*

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725920] be either a physician , certified physician â€™s assistant, or advanced registered 
nurse practitioner.  
Whenever possible , the same investigator should perform all the evaluations for a given 
subject throughout the entire trial period  to reduce inter -rater variability . 
AEs must be assessed by [CONTACT_82048]  (i.e. adequately trained medical 
doctors) (Section  13.2). 
11.2 Assessments performed only at screening/baseline  
11.2.1  Demographics  
The following demographic data will be recorded:  
ï‚· Date of birth. If full date of birth is not allowed to be recorded, month and year 
of birth should be collected together with the subject â€™s age .  
ï‚· Sex: female, male . 
ï‚· Race: American Indian or Alaska native, Asi an, b lack or African American, 
native Hawaiian or other Pacific islander, white, other (requires a specification 
to be provided) . 
ï‚· Ethnic origin (self -reported by [CONTACT_748]): Hispanic or Latino, not Hispanic 
or Latino . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725921] â€™s skin type will be recorded using the Fitzpatrick skin classification ( Panel 7).  
Panel 7: Fitzpatrick skin classification  
Skin type  Description  
I Individuals who never tan and always sunburn if exposed to any appreciable amount 
of sunlight, primarily red -headed individuals and lightly complected blondes.  
II Individuals who frequently burn but are able to tan to a small degree after extended 
sun exposure.  
III Individuals who burn infrequently and tan readily.  
IV Individuals who rarely burn and tan heavily with moderate sun exposures, 
especially individuals of Asian, American Indian, Mediterranean and Latin 
American descent.  
V Individuals who have dark constitutive pi[INVESTIGATOR_552285], especially light  complected black individuals, those of Indian 
descent.  
VI Individuals who have the heaviest constitutive pi[INVESTIGATOR_371], especially dark 
skinned black individuals.  
 
11.2.[ADDRESS_725922] â€™s birth must be recorded.   
ï‚· Skin disease history: all past and current skin disease history including:  
o Alopecia .  
o Vitiligo . 
o Herpes simplex . 
ï‚· Atopy history:  
o Onset of AD disease . 
o Previous treatments  for AD .  
o Asthma . 
o Food allergy . 
o Hay fever . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725923].  
o Glaucoma.  
o Eczema herpeticum . 
ï‚· Other medical and surgical history including concurrent diagnoses  within the 
previous [ADDRESS_725924] â€™s height (without shoes) will be measured; the subject â€™s weight (in indoor 
clothing and without shoes) will be measured . 
11.2.5  Body surface area involvement  
The total BSA  affected by [CONTACT_552315] A of SCORAD (see Section  11.3.3 ) and will be reported as a percentage o f all 
major body sections combined. The following body regions will be assessed  (with the highest 
possible score for each region in brackets): head and neck (9%), anterior trunk (18%), back 
(18%), upper limbs (18%), lower limbs (36%) and genitals (1%).  
The total BSA score will be assessed according to the schedule of procedures ( Panel 2). 
11.3 Efficacy assessments  
11.3.1  Eczema Area and Severity Index (EASI)  
The EASI is a validated measure used in clinical practice and clinical trials to assess the 
severity and extent of AD  (Hanifin et al. 2001 , Tofte et al. 1998 ). The EASI score will be 
assessed according to  the schedule of trial procedures (Section  4). The assessment will be 
based on the condition of the disease at the time of evaluation and not in relation to th e 
condition at a previous visit . 
The EASI is a composite index with scores ra nging from 0 to 72, with higher values 
indicating more severe or more extensive condition . The index will be calculated as shown in 
Panel 8. Briefly, t he investigator will assess the severity of 4  AD disease characteristics 
(erythema, induration/papulation, excoriation, and lichenification) on the 4 body regions 
(head/neck, trunk, upper extremities , lower extremities ); severity will be assessed according  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725925] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
to the scale shown in Panel 9. For each body region, a severity sum score will be calculated 
which will be multiplied by [CONTACT_73307] (Panel 9) and by a weigh ting factor . The EASI score 
equals the sum of the scores obtained for each body region ( Panel 8). The EASI score will be 
calculated  automatically . 
Panel 8: Calculation of the Eczema Area and Severity Index  
Body region  
Erythema  
Induration / 
papulation  
Excoriation  
Lichenification  
Area score  
Weigh ting factor  
Score  
Head/ neck  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.1   
Trunk  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.3   
Upper extremities  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.2   
Lower extremities  ( SS   +     SS   +     SS   +     SS ) x  AS  x 0.4   
The EASI score is the sum of the 4 body region scores   
(range 0â€“72) 
AS, area score; EASI, Eczema Area and Severity Index;  SS, severity score. Modified from  (HOME website ). 
Panel 9: EASI severity score scale and area score scale  
Severity score scale   Area score scale  
0 None/absent   0 0% affected area  
1 Mild   1 1% to 9% affected area  
2 Moderate   2 10% to 29% affected area  
3 Severe   3 30% to 49% affected area  
Note: h alf-steps (0.5, 1.5, 2.5) are 
allowed.   4 50% to 69% affected area  
 5 70% to 89% affected area  
 6 90% to 100% affected area  
EASI, Eczema Area and Severity Index  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725926] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
11.3.2  Validated Investigator Global Assessment scale for Atopic Dermatitis  
(vIGA -AD) 
The vIGA -AD is an instrument used in clinical trials to assess the subject â€™s global disease 
severity  and is based on a 5 -point scale ranging from 0 (clear) to 4 (severe) ( Panel 10). The 
vIGA -AD score will be assessed at time points according to the schedule of trial procedures 
(Section  4). The ass essment will be based on the condition of the disease at the time of 
evaluation and not in relation to the condition at a previous visit. New lesions that occurred on 
previously untreated areas will be included in the assessment.  
The vIGA -AD score is selec ted using the descriptors in Panel [ADDRESS_725927] describe the overall 
appearance of the lesions at a given time point. It is not necessary that all char acteristics under 
morphological description be present.  
Panel 10: Validated Investigator Global Assessment scale for Atopic Dermatitis  
Score  Morphological description  
0 - Clear  No inflammatory signs of atopic dermatitis (no erythema, 
no induration/papulation, no lichenification, no 
oozing/crusting). Post -inflammatory hyperpi[INVESTIGATOR_119065]/or hypopi[INVESTIGATOR_22765].  
[ADDRESS_725928] clear  Barely perceptible erythema, and barely perceptible 
induration/papulation, and/or min imal lichenification. No 
oozing or crusting.  
2 - Mild  Slight but definite erythema (pi[INVESTIGATOR_8745]), slight but definite 
induration/papulation, and/or slight but definite 
lichenification. No oozing or crusting.  
3 - Moderate  Clearly perceptible erythema (dull red),  clearly perceptible 
induration/papulation, and/or clearly perceptible 
lichenification. Oozing and crusting may be present.  
4 - Severe  Marked erythema (deep or bright red), marked 
induration/papulation, and/or marked lichenification. 
Disease is widespread  in extent. Oozing or crusting may be 
present.  
Reference: Eli Lilly and Company 2017  
11.3.3  Scoring Atopic Dermatitis  (SCORAD)  
The SCORAD is a validated tool to evaluate the extent and severity of AD  lesions,  along with 
subjective symptoms  (European Task Force on Atopic Dermatitis 1993 ). The maximum total 
score is 103, with higher values indicating more severe disease. SCORAD will be assessed 
according to the schedule of trial procedu res (Section  4). 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725929] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The assessment will be based on the condition of the disease at the time of evaluation and not 
in relation to the condition at a pr evious visit. Whenever possible, SCORAD should be 
assessed by [CONTACT_421467] -rater variability.  
The assessment consists of 3 components: A = extent , B = intensity , and C = subjective 
symptoms . 
Extent (A)  
The extent  of AD is assessed as a percentage of each defined body area and reported as the 
sum of all areas (maximum score = 100%) . 
Intensity (B)  
The intensity  of 6 specific symptoms of AD (erythema, edema/p apulation, oozing/crusting , 
excoriation, lichenification , and dryness) is assessed by [CONTACT_421468]:  
0 = None/absent  
1 = Mild 
2 = Moderate  
3 = Severe  
Note: dryness is evaluated on uninvolved areas.  
The sum of intensity score of the 6 symptoms  will be reported (maximum score = 18 ). 
Subjective symptoms (C)  
A subjective assessment of the average itch and sleeplessness over the last 3  days/nights is 
recorded for each symptom by [CONTACT_1175] a visual analogue scale , where 0 is no itch ing (or 
no trouble sleepi[INVESTIGATOR_007] ) and 10 is unbearable itching  (a lot of trouble sleepi[INVESTIGATOR_007] ), with a maximum 
possible score of 20.  The s ubjective assessment will be completed by [CONTACT_552316].  
The SCORAD is calculated  as: A/5+7B/2+C . The SCORAD will be calculated automatically.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725930] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
11.4 Safety assessments  
11.4.1  Vital signs 
Vital signs (resting blood pressure, pulse , and body temperature) will  be assessed according to 
the schedule of trial procedures (Section  4). Vital signs will be measured in a supi[INVESTIGATOR_547689] [ADDRESS_725931] should be r andomis ed 
into the trial  (respecting exclusion criterion no. 20) . 
In case of abnormal findings , the vital sign measurement c an be repeated approximately 
[ADDRESS_725932] measurement verifies the second (normal) value, the first measurement 
should be considered false. If the third measurement confirms the first measurement 
(abnormal) , the second measurement will be considered false. Only the last value measured 
and considered correct will be recorded in the eCRF.  
Reporting in eCRF  
Vital signs  will be recorded in the eCRF. Clinically significant a bnormal vital signs at the 
screening visit will be documented as medical history in the eCRF. At subsequent visits, any 
clinically significant deterioration of a pre -existing condition as well as any n ew clinically 
significant sign, symptom or illness will be reported as an AE in accordance with 
Section  13.3. 
11.4.[ADDRESS_725933] including whole body inspection of the skin 
and auscultation of heart, lungs and abdomen; palpi[INVESTIGATOR_552286] 
(Section  4). The investigator should perform the same examinations as in clinical practice as a 
minimum.  
If the screening physical examination results in a finding,  which is abnormal and of clinical 
significance, it will be at the investigator â€™s discretion to decide if the subject shoul d be 
randomised into the trial (respecting exclusion criterion no. 20).  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725934] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Reporting in eCRF  
It will be recorded in the eCRF if a physical examination was performed and the 
investigator â€™s evaluation  (â€˜normal â€™, â€˜abnormal, not clinically significant â€™, â€˜abnormal, 
clinically significant â€™); if a physical examination was not performed, a reason must  be given. 
Clinically significant abnormal findings at the screening visit  will be documented as medical 
history in the eCRF. At subsequent visits, any clinically significant deterioration of a pre -
existing condition as well as any new clinically significant si gn, symptom or illness will be 
reported as an AE in accordance with Section  13.3. 
11.4.[ADDRESS_725935] 5 minutes at the visits indicated in the schedule of trial procedures (Section  4). 
A preliminary  evaluation  of the ECGs will be performed by [CONTACT_552317]. As  a minimum , the date of ECG collection will be recorded in the 
source documents.  
The ECG data will be transferred to a central ECG service company for ce ntral evaluation. A 
cardiologist at the ECG service company will analyse and interpret the ECG data. The ECG 
service company will provide ECG evalua tion reports to the trial sites.  
The investigator must evaluate all abnormal ECG results (â€˜clinically significant â€™ or â€˜not 
clinically significant â€™) and sign and date.  The investigator has the final decision on the clinical 
significance of ECG abnormalities.  
If the screening ECG  result s in a finding, which is abnormal and of clinical significance , it 
will b e at the investigator â€™s discretio n to decide  if the subject should be randomised  into the 
trial (respecting exclusion criterion no. 20) .  
The collection and transmission of ECG data will be desc ribed in a separate ECG manual.  
Test dummy transmissions will be undertaken prior to the trial conduct to ensure that 
transmissions can be made,  and that date and time settings are correctly set.  
Reporting in eCRF  
It will be recorded in the eCRF if an ECG was performed and the investigator â€™s assessment of 
ECG results  (â€˜normal â€™, â€˜abnormal, not clinically significant â€™, â€˜abnormal, clinically 
significant â€™); if an ECG was not perfo rmed, a reason must  be given.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725936] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Clinically significant abnormal findings at the screening visit will be documented as medical 
history in the eCRF.  At subsequent visits, any clinically significant deterioration of a 
pre-existing condition as well as any new clinically significant sign, symptom or illness will 
be reported as an AE in accordance with Section  13.3. 
11.4.4  Laboratory  testing  
Blood and urine s amples will be collected according to the schedule of trial procedures 
(Section 4). See Panel 11 for an overview of the individual clinical laboratory parameters to 
be assessed in this trial.  
Central laboratory  
Chemistry, haematology, urinalysis (if applicable), serology, and serum pregn ancy tests will 
be analysed by a central laboratory which will provide results to the trial sites. The 
investigator must evaluate all results outside the reference range (â€˜clinically significant â€™ or 
â€˜not clinically significant â€™) and sign and date. The sign ed and dated version will be filed with 
the investigator â€™s trial documentation. Clinically significant abnormal tests must be repeated 
to confirm the abnormality.  
If a screening laboratory result is abnormal and of clinical significance, it will be at the 
investigator â€™s discretion to decide if the subject should be randomised into the trial  
(respecting exclusion criteri a no. 16, 20, 21, 22, and 29 ).  
A laboratory manual will be provided to the trial sites specifying the procedures for 
collection, processing, storage, and shipment of samples, as well as laboratory contact 
[CONTACT_483628].  
Tests performed at the trial site  
Urine samples will be tested at the trial site with a dipstick; if abnormal, a urine sample will 
be sent to th e central laboratory for further analysis.  
Women  of childbearing potential will have a urine pregnancy test performed at the trial site at 
visits indicated  in the schedule of trial procedures in Section  4.  
 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725937] in the eCRF if a sample was taken and the investigator â€™s assessment 
of the results (â€˜normal â€™, â€˜abnormal, not clinically significant â€™, â€˜abnormal, clinically 
significant â€™). 
The date and the outcome of the urine pregnancy test will be recorded in the eCRF (â€˜positive â€™, 
â€˜negative â€™). 
Clinically significant abnormal laboratory results at the screening visit will be documented as 
medical history in the eCRF. At subsequent visits, any clinically significant deterioration of a 
pre-existing condition as well as any new clinically significant sign, symptom or illness will 
be reported as an AE in accordance with Section  13.3. 
11.4.[ADDRESS_725938] assessment of local tolerability  
Subjects will provide an assessment of local tolerability according to the schedule of trial 
procedures (Section 4).  
The subject will retrospectively be asked by [CONTACT_552318]/burning in 
connection with the IMP applications since their last visit. The highest (worst) skin reaction 
score across treatment area(s) will be recorded in the eCRF by [CONTACT_324011] 4 -point scale shown 
in Panel 12. 
Panel 12: Subject assessment of local tolerability after IMP application  
Grade  Stinging/burning  
0 (none)  No stinging or burning  
1 (mild)  Slight warm, tingling sensation, not really 
bothersome  
2 (moderate)  Definitive warm, tingling sensation, that is 
somewhat bothersome  
3 (severe)  Hot, tingling/stinging sensation that has 
caused definite discomfort  
 
Subject assessment of local tolerability will be performed after safety assessments by [CONTACT_1275] ( Panel 6). Local tolerability reactions are not reported as AEs; however, if they 
qualify as an SAE, they will be reported as described in Section 13.4.1 . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725939] after 2â€“6 hours 
after the morning application of IMP as specified in the schedule of trial procedures 
(Section  4). The PK blood sample should be collected from a non -treated area.  
It will be recorded in the eCRF if the PK blood sample was taken; if not, a reason will be 
provided.  The date  and time of the last IMP application prior to the PK sample being taken 
must be recorded in the eCRF.  
Collection, handling and shipment instructio ns for PK blood samples are provided in a 
laboratory manual.  
Plasma samples for determination of delgocitinib  concentration will be analysed by a 
laboratory using a validated bioanalytical method. Details of the analytical method used will 
be described in the bioanalytical report.  
Samples from delgocitinib  cream vehicle -treated subjects will not be analysed.  Written 
procedures are in place to avoid unblinding of the trial and any trial subjects  in relation to 
analysis of the PK samples.  
11.6 Pharmacodynamic s and  pharmacogenomics  
11.6.1  Overview  
Normal skin is colonised by a wide variety of microorganisms, including fungi, viruses, and 
bacteria. The skin microbiome is complex and diverse and varies between individuals and 
anatomical sites ( Costello et al. 2009 ). It has been known for years that some skin diseases are 
associated with dysbiosis of the skinbiome. AD has long been associated with increased skin 
colonisation with S. aureus . Indeed, S. aureus  colonisation has been proposed to pla y an 
important role in AD pathophysiology via bacterial production of specific virulence factors 
(Cardona et al. 2006 ). Increased colonisation with S. aureus  in AD is accompanied by 
[CONTACT_552319], resulting in overall decrease 
in bacterial diversity ( Kong et al. 2012 ). Resolution of active -disease in AD in response to 
therapy correlates with reduction of S. aureus  colonisation and increase in microbiome  
diversity ( Kong et al. 2012 ). 
The present trial will use sequencing to identify specific strains of bacteria present on the skin 
and thus characterise treatment effects on the skin microbiome in AD subjects.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725940] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
A summary of the re sults will be include d in the CTR if they are available in time for this. 
The full pharmacodynamics/biomarker results will be reported in an addendum report to the 
CTR.  
11.6.2  Skin swabs  
A total of 4 skin swabs for microbiome and S. aureus  measurement s will be taken at the time 
points specified in the schedule of trial procedures (Section 4). 
At baseline (Day  1), 2 skin swabs are to be taken:  
ï‚· 1 skin swab from a representative lesional area. The location should be 
selected so that a similar non -lesional body location can be identified.  
ï‚· 1 skin swab from a non -lesional area at an anatomically similar site to the 
lesional skin swab.  
At We ek 8 (end of treatment), 2  skin swab s will be taken at the same locations  as the baseline 
skin swab s. 
If biopsies are to be taken (see Section  11.6.3 ), the baseline biopsies will be ta ken from the 
same area  as the skin swabs, so the sites selected for skin swabs must then also be appropriate 
for biopsying.  
It will be recorded in the eCRF if the skin swab s were taken and from which location  (volar 
arm, lower limbs, trunk, other ); if skin swab s were  not taken, a comment will be provided.  
Subjects will be instructed not to shower or wash their body for at least 1 0 hours prior to the 
baseline visit and Week 8 visit.  
Further instructions for collection, handling and shipment for skin swabs are provi ded in a 
laboratory manual.  
11.6.3  Skin biopsies  and photographs  (all sites, but optional ) 
Subjects  who have lesions at a location su itable for biopsying (i.e. volar arm, lower limbs, 
trunk, other) will be asked to participate in an exploratory component involving skin biopsies. 
Participation in this component of the trial requires that the subject provides additional 
informed consent  and is not  mandatory for participation in the trial . Biopsies will  not be taken 
if the investigator considers the procedure unsuitable for the subject (e.g. subjects receiving 
anticoagulant therapy).  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725941] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
It is expected that approximately half of the eligible subjects will accept to participate in this 
exploratory component of the trial. If biopsies are obtained from less than 10% of subjects, 
analysis may not be carried out as the number of biopsies may be to too low to allow for a 
meaningful analysis. A final decision will be made after unblinding.  
The skin biopsies will b e used to analyse the expression of genes involved in the pathogenesis 
of AD including inflammatory genes, genes involved in immune function and genes involved 
in skin differentiation and barrier function. If deemed relevant transcriptome profiling of some  
or all of the biopsies may be done. The pu rpose is to assess if changes in  gene expression 
precedes the clinical effect of JAK inhibition and to show disease resolution also at the 
molecular level.  
A total of four s kin biopsies ( 2 mm) will be taken at the timepoints  specified in the schedule 
of trial procedures (Section 4): at baseline (lesional and non -lesional skin), after 1 week of 
treatment (lesi onal only) and at end of treatment (lesional only) .  
Skin biopsies will be taken from the same body location as the skin swabs. It will be recorded 
in the eCRF if the biopsy was taken and from which body location (volar arm, lower limbs, 
trunk, other); if not, a comment should be provided. All four biopsies will be from an 
anatomically similar body location to the extent possible.  
A check of skin biopsy wound healing including removal of suture, if applicable, will be 
performed at the next trial visit as s pecified in the schedule of trial procedures (Section 4). 
The biopsies will be transferred to RNAlater (RNA stabilisation) solution immediately after 
being collected and placed at 2â€“8Â°C for 16â€“30 hours. The sample will then be transferred to  a 
clean tube and stored at  <-20Â°C in sui table rack and ke pt until shipment to the central 
laboratory for further processing. Further instructions for collection, handling , and shipment 
for skin biopsy samples are provided in a laboratory manual.  
It is recommended to document the biopsied areas with photographs taken before biopsying 
and immediately after, both at baseline, after 1 week of treatment and at the end of treatm ent, 
using digital photography assessments. This will serve both as a documentation of the biopsy 
site and to show disease progression over time. The photography component for the skin 
biopsies is recommended and not mandatory.  
The trial sites participatin g in this photography component will be expected to use their own 
equipment to take the photographs. Instructions and specifications for photography will be 
provided in a photography manual.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725942] is protected to the extent possible.  
11.7 Other assessments  
11.7.1  Patient -reported outcomes  (PROs)  
Each subject must make individual assessments relating to their perception of their disease 
and quality of life. These will be performed prior to the investigator performing his/her 
efficacy assessments . At the screening visit, the subject â€™s eligibility needs to be established 
before the PROs can be completed.  
The subjects will receive an eDiary device and eDiary training, as well  as complete all of the 
PROs  (except TSQM) , at the screening  visit. Completion of the eDiary will be initiated at the 
latest 1 week prior to the baseline visit (Day 1).  
Two PROs will be assessed daily using an eDiary:  
ï‚· ADSD . 
ï‚· Eczema -related Sleep NRS . 
The subjects must complete the eDiary  each day in the evening , and compliance with the 
eDiary completion wi ll be reviewed by [CONTACT_73279] . The eDiary 
should be returned to the trial site as  outlined in the schedule of trial procedures (Section 4). 
In addition, 8 PROs will be completed on an electronic device by [CONTACT_552320] (Section 4). The PROs will be 
completed  in the following order : 
ï‚· POEM . 

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

x'/4,
x3*,6
x3*,&
x6)
x(4'/
x:/4
x7640
$WRSLF'HUPDWLWLV 6\PSWRP'LDU\ $'6'
$'6'LVDV\PSWRPGLDU\GHYHORSHGE\/(2 





(F]HPDUHODWHG6OHHS1XPHULF5DWLQJ6FDOH(F]HPDUHODWHG6OHHS
156
(F]HPDUHODWHG6OHHS156LVDVFDOHGHYHORSHGE\/(2 6XEMHFWVZLOOUDWHKRZPXFKWKHLU
HF]HPDLQWHUIHUHGZLWKWKHLUVOHHSWKH SUHYLRXVQLJKWXVLQJDQ SRLQW156LQGLFDWLQJLW
ÂµGLGQRWLQWHUIHUH Â¶DQGLQGLFDWLQJWKDWLW ÂµFRPSOHWHO\LQWHUIHUHG Â¶6XEMHFWVZLOOFRPSOHWHWKH
(F]HPDUHODWHG6OHHS156DVSDUWRIDQH'LDU \HDFKGD\LQWKH HYHQLQJDWWKHODWHVW IURP
:HHNWR:HHN 
3DWLHQW2ULHQWHG(F]HPD0HDVXUH 32(0
32(0LVDYDOLGDWHGTXHVWL RQQDLUHXVHGWRDVVHVVGLVHDVH V\PSWRPVLQ$'SDWLHQWVLQERWK
FOLQLFDOSUDFWLFHDQGFOLQLFDOWULDOV &KDUPDQHWDO 
7KHWRROFRQVLVWVRILWH PVHDFKDGGUHVVLQJD VSHFLILFV\PSWRP LWFKLQJVOHHSEOHHGLQJ
ZHHSLQJFUDFNLQJIODNLQJDQGGU\QHVV 6XEMHFWVZLOOVFRUHKRZRIWHQWKH\ KDYHH[SHULHQFHG
HDFKV\PSWRPRYHUWKHSUHYLRXVZHHNRQD SRLQWFDWHJRULFDOUHVSRQVHVFDOH  ÂµQRGD\VÂ¶
 ÂµWRGD\VÂ¶ ÂµWRGD\VÂ¶ ÂµWRÂ¶GD\V ÂµHYHU\GD\Â¶7KHWRWDOVFRUHLVWKH
VXPRIWKH LWHPVUDQJHWRDQGUHIOHFWVGLVHDVH UHODWHGPRUELGLW\DKLJKVFRUHLVCCI
CCI
CCI
CCI CCI
Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725943] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
indicative of a worse disease severity. The POEM will be completed at the trial site according 
to the schedule of trial procedures ( Panel 2). 
[IP_ADDRESS]  Dermatology Life Quality Index  (DLQI)  
DLQI is a validated questionnaire with content specific to those with dermatology conditions. 
It consists of [ADDRESS_725944] â€™s percepti on of the impact of their skin disease 
on different aspects of their quality of life over the last week. These include dermatology -
related symptoms and feelings, daily activities, leisure, work or school, personal relationships 
and the treatment ( Finlay & Khan 1994 ). Each item is sco red on a 4 -point Likert scale (0 =â€™not 
at all/not relevant â€™; 1=â€™ a little â€™; 2=â€™ a lotâ€™; 3=â€™ very much â€). The total score is the sum of the 10 
items (0 to 30); a high score is indicative of a poor qu ality of life. The DLQI will be 
completed at the trial site according to the schedule of trial procedures  in Section 4.  
[IP_ADDRESS]  Patient Global Impression of Severity (PGI -S) 
PGI-S is a single item designed to capture the subject â€™s overall perception of their eczema 
over the past week  on a 4 -point categorical response scale (â€˜none â€™ to â€˜severe â€™). The PGI -S will 
be completed at the trial site according to the schedule of trial procedures (Section 4). 
[IP_ADDRESS]  Patient Global Impression of Change (PGI -C) 
The PGI -C is a 1-item questionnaire designed to assess the subject â€™s overall impression of 
changes ( FDA public workshop on Guidance 3 2018 ). The subjects have to select the one 
response from the response options (â€˜much better â€™, â€˜a little be tterâ€™, â€˜no change â€™, â€˜a little 
worse â€™, or â€˜much worse â€™) that best describes the overall change in their eczema since they 
started IMP treatment. The PGI -C will be completed at the trial site according to the schedule 
of trial procedures in Section 4. 
[IP_ADDRESS]  36-item Short Form Health Survey ( SF-36) 
The SF -36v2 (Acute Recall) is a 36 -item scale constructed to survey health status and quality 
of life ( Ware & Sherbourne 1992 ). The acute recall version asks subjects to reply to questions 
according to how they have felt over the previous week. Subjects will be asked to answer 
each item by [CONTACT_128065] 3 to 6 categori cal response options.  
The SF -36v2 (Acute Recall) yields scores for 8 health domains (physical functioning, role 
physical, bodily pain, general health, vitality, social functioning, role emotional, and mental 
health) and 2 psychometrically derived summary s cores (a physical component summary and 
a mental component summary).  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725945] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The SF -36 will be completed according to the schedule of trial procedures in Section 4.  
[IP_ADDRESS]  EuroQol 5 -dimension health questionnaire 5 -level ( EQ-5D-5L) 
EQ-5D-5L is a standardised measure of health status developed by [CONTACT_552321] a simple, generic measure of health  for clinical and economic appraisal ( Greiner et al. 
2003 ). The EQ -5D-5L is a self -administered questionnaire used to assess health status â€˜today â€™ 
and is divided into [ADDRESS_725946] section includes 5 dimensions (mobil ity, self -care, 
usual activity, pain/discomfort, and anxiety/depression); each dimension will be assessed by 
[CONTACT_48681] a 5 -point Likert scale (â€˜no problems â€™, â€˜slight problems â€™, â€˜moderate 
problems â€™, â€˜severe problems â€™, and â€˜extreme problems â€™). The se cond section consists of a 
vertical visual analogu e scale anchored at 0 (â€˜the worst  health you c an imagine â€™) and 100 (â€˜the 
best health you can imagine â€™). The EQ -5D-5L will be completed at the trial site according to 
the schedule of trial procedures in Section 4. 
[IP_ADDRESS]  Work Limitation Questionnaire  (WLQ)  
WLQ is a validated questionnaire to measure the degree to which health problems interfere 
with specific aspects of job performance and the productivity impact of these work 
limitations  (Lerner et al. 2001 ). It asks subjects to rate their level of difficulty or ability to 
perform [ADDRESS_725947] 2 weeks. Responses to the 25 items are combined 
into 4  work limitation scales: time management, physical demands, mental/interpersonal, and 
output demands. These capture the multidimensionality of job roles and also reflect an 
important characteristic of many chronic illnesses, in tha t they may result in limitations in 
performing some activities but not others. Scale score range from 0 (â€˜limited none of the 
timeâ€™) to 100 (â€˜limited all the time â€™). The WLQ will be completed at the trial site for subjects 
with a paid job according to the schedule of trial procedures in Section  4.  
[IP_ADDRESS]  Treatment Satisfaction Questionnaire for Medicine  (TSQM)  
The TSQM v. II is a generic questionnaire assessing subject â€™s satisfaction with the treatment 
(Atkinson et al. 2004 ). The tool consists of 11 items addressing four domains (effectiveness, 
side effects, convenience and overall satisfaction). Ten items will be assessed by [CONTACT_552322] a 7 -point scale (â€˜extremely dissatisfied â€™, â€˜very dissatisfied â€™, â€˜dissatisfied â€™, â€˜somewhat 
satisfied â€™, â€˜satisfied â€™, â€˜very satisfied â€™, and â€˜extremely satisfied â€™). However, one item will be 
assessed using a 2 -point scale (â€˜yesâ€™ and â€˜noâ€™). The score ranges from 0 to 100 with higher 
scores indicating higher satisfaction. The TSQM will be completed at the trial site according 
to the schedule of trial procedures ( Panel 2). 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725948]  AD lesions on scalp will be captured  in the eCRF as specified in the 
schedule of trial procedures (Section 4). 
11.[ADDRESS_725949] (females of ch ildbearing  potential only). The total volume of blood to be 
drawn is approximately [ADDRESS_725950] be  completed i n the eCRF for all randomised  subjects  (including 
subjects who permanently discontinue IMP and subjects who withdraw from trial) . The 
following data will be collected:   
ï‚· Whether the subjects completed the trial . 
ï‚· Last trial site  visit or contact [CONTACT_398860] w hich data is recorded . 
ï‚· Date and time of last application  of IMP.  
ï‚· Primary reaso ns for discontinuation from IMP , withdrawal from trial, and not 
attending primary endpoint visit, if applicable (lack of efficacy, AE, 
withdrawal by [CONTACT_1130], lost to follow -up, pregnancy, death, other) . 
The end of trial form will be completed when the subject has had their last visit  (at the early 
termination visit, the safety follow -up visit, or the primary endpoint visit, whichever comes 
last). 
11.10  Storage of biological samples  
PK samples  and skin biopsies  will be retained for as long as the quality of the material 
permits evaluation but for no longer than 12 months  after completion of the CTR  unless 
specific additional consent has been obtained that allows storage for future research (see 
below) . 
  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725951] the privacy of the subjects and to allow continued blinding 
for future analyses. The samples from this trial will be stored in the biobank for  up to 10  years 
after the end of the tr ial and will then be destroyed.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725952] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
12 Scientific rat ionale for trial design and a ppropriateness of assessments  
This is a multi -centre, randomised, vehicle -controlled, double -blind, parallel -group trial, 
which will be conducted in accordance with the protocol, ICH -GCP and applicable regulatory 
requirements.  
The trial will be conducted at multiple trial sites located in North America ([LOCATION_003] and Canada) 
and Australia. High -quality trial sites with shared standards of practice and values will be 
selected.  
Patients with AD represent a heterogeneous patient populati on with disease severity ranging 
from mild  to severe. To mitigate any pot ential difference in trial outcome based on baseline 
characteristics, eligibility criteria for  inclusion  have been carefully selected and trial subjects 
will be randomised in stratifi ed manner as described in Section 9.3. The randomisation will 
minimise selection bias and minimise influence of (intrinsic) confounding factors and the 
stratificat ion will ensure a certain balance of the treatment groups with respect to disease 
severity  and region .  
The most important inclusion criteria for entry into the trial is a diagnosis of AD (as defined 
by [CONTACT_85811] 1980 criteria ( Hanifin & Rajka 1980 , Appendix 6 ) and history  of 
AD for at least [ADDRESS_725953] diagnosis and rule out differential diagnosis.  
The inclusion of 4 active treatment arms with 1, 3, 8 and 20 mg/g of delgocitinib  cream and a 
vehicle control group  is considered enough  to establish a  dose-response signal. The vehicle 
control group will serve as reference and has been added to establish the efficacy and safety 
of the delgocitinib  cream in a blinded trial design.  
The trial endpoints have been selected to evaluate the efficacy of delgocitinib  in improving 
the severity and extent of AD. EASI, vIGA-AD and SCORAD will be used in this clinical 
trial as investigator -rated assessments of disease severity. EASI is a validated measure used in 
clinical practice and clinical trials to assess the severity and extent of AD ( Hanifin et al. 2001 , 
Tofte et al. 1998 ). vIGA-AD is a validated instrument  used in clinic al trials to assess  the 
subject â€™s global AD and SCORAD is a validated tool to assess the extent and severity of AD 
lesions and subjective symptoms ( European Task Force on Atopic Dermatitis 1993 ). The 
primary endpoint of the trial is to evaluate t he change in EASI score from baseline to Week 8. 
The trial endpoints will also address subject â€™s perception of disease severity and the impact on 
sleep, daily activity, and health -related quality of life , and safety .  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725954] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The duration of this t rial is 8 week s. This duration - based on results from a phase 2a trial in 
adults  with the ointment formulation ( Nakagawa et al. 2018 ) - is considered to be sufficient to 
evaluate the duration required for optim al treatment effect . 
 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725955] (defined as safety follow -up 
visit [ADDRESS_725956] IMP administration) . 
AEs must be assessed by [CONTACT_82048].  
At all visits, the subject will be asked a non -leading question by [CONTACT_73318], 
for example : â€œHow have you felt since I saw you last?â€ No specific symptoms should  be 
asked for. It is important that the investigator  also observes the subject for any changes not 
reported by [CONTACT_73319].  If a subject report an AE during the phone 
call on Day 4, it is up to the investigator â€™s discretion to per form an unscheduled visit.  
Refer to Sections 11.4.[ADDRESS_725957] be recorded on the AE form 
of the eCRF and should be described in the following manner:  
The AE term must  be in precise English medical terminology ( that is, not necessarily the exact 
words used by [CONTACT_423]). Whenever possible, a specific diagnosis should be stated ( for 
example  â€˜allergic contact [CONTACT_8748] â€™). 
For cutaneous AEs,  the location  must be part of the AE description and may be described as 
[e.g. the face, scalp, back, chest, arm, leg, trunk or limb]. Additionally, the location should be 
described us ing the following terminology:  
ï‚· Lesional/perilesional (â‰¤2 cm from the border of lesion (s) treated with IMP) .  
ï‚· Distant (>2 cm from the lesion border) . 

7ULDO,'/3 'DWH$XJ 9HUVLRQ
3DJHRI

7+,6'2&80(17&217$,16&21),'(17,$/,1)250$7,21$1'0867127%( &23,('250$'($9$,/$%/(72$1<7+,5'3$57<:,7+287
7+(35,25:5,77(1 &216(172)7+(/(2*5283

7KHGXUDWLRQRIWKH$(PXVW EHUHSRUWHG E\WKHVWDUWGDWHDQGVWRSGDWHRIWKHHYHQW LWZLOO
DOVREHUHFRUGHGLI WKHHYHQWLVRQJRLQJ ,QDGGLWLRQLWZLOOEHUHFRUGHGLIWKH$(VWDUWHGSULR U
WRVWDUWRI,03 
$(VPXVWEHFODVVLILHGLQWHUPVRIVHYHULW\FDXVDOLW\DQGRXWF RPHDFFRUGLQJWR WKHGHILQLWLRQV
LQ$SSHQGL[ 
$FWLRQWDNHQZLWK ,03DQ\DFWLRQWDNHQZLWK ,03DVDFRQVHTXHQFHRIWKH$(PXVW EH
UHFRUGHGGRVHQRWFKDQJHG GUXJZLWKGUDZQQRWDSSOLFDEOHXQNQRZQ 
2WKHUDFWLRQWDNHQ DQ\RWKHUDFWLRQWDN HQDVDUHVXOWRIWKH $(PXVWEHUHFRUGHG QRQH
FRQFRPLWDQWPHG LFDWLRQFRQFXUUHQW SURFHGXUH 
:LWKGUDZQ IURPWULDO GXHWRWKLV$(LWPXVWEHUHFRUGHGZKHWKHUWKH$(OHG WRZLWKGUDZDO
IURPWKHWULDO 
5HSRUWLQJRIVHULRXVDGYHUVHHYHQWV 
7KHFULWHULDWKDW GHILQHDQ$(DVVHULRXV WKDWLVDQ6$(DUHGHILQHGLQ $SSHQGL[ 6$(
FULWHULDDUHDOVROLVWHGRQ WKH6$(IRUP
,QYHVWLJDWRUUHSRUWLQJ UHVSRQVLELOLWLHV 
$Q\6$(PXVWEHUHSRUWH GWR/(2RQWKHSDSHU6$( IRUPZLWKLQ KRXUVRIILUVW
NQRZOHGJH7KLVUHSRUWVKRXOGFRQWDLQDQD VVHVVPHQWRIDYDLODEO HLQIRUPDWLRQRQVHULRXVQHVV
VHYHULW\FDXVDOUHODWLRQV KLSWRWKH,03FRPSDUDWRURUWULDOS URFHGXUHWKHDFWLR QWDNHQWKH
RXWFRPHWRGDWHDQGDQDUUDWLY HGHVFULSWLRQRIWKHFRXUVHRIW KHHYHQW
7KHFRPSOHWHG6$(IRUPPXVWEH ID[HGRUVFDQQHGDQGH PDLOHGWR *OREDO
3KDUPDFRYLJLODQFHDW /(2XVLQJWKH HPDLODGGUHVVRU ID[QXPEHU EHORZ
*OREDO3KDU PDFRYLJLODQFHDW /(2
(PDLODGGUHVV 
)D[QXPEHU 
,IUHOHYDQWWKHLQYHVWLJDWRUZLOO HQFORVHRWKHULQIRUPDWLRQZLWKW KH6$(IRUPVXFKDV
DQRQ\PLVHGUHSRUWVRIGLDJQRVWLFSURFHGXUHVKRVSLWDOUHFRUGV DXWRSV\UHSRUWVHWF CCICCI
Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725958] by 
[CONTACT_3719] e -mail (see contact [CONTACT_73322]).  
The investigator must notify the local IRB(s)/IEC(s) of SAEs , as required by [CONTACT_82050].  
SAEs occurring after the completion of the clinical trial should not be routinely sought or 
collected. However, such events should be reported to Global Pharmac ovigilance  at LEO ( see 
contact [CONTACT_73322] ) if the investigator becomes aware of them.  
13.4.2  LEO r eporting responsibilities  
Global Pharmacovigilance at LEO is responsible for assessing whether or not an SAE is 
expected. The relevant reference  safety informatio n document  for this clinical trial is:  
For the IMP, the In vestigator â€™s Brochure  for delgocitinib  cream , edition [ADDRESS_725959] be used.   
Global Pharmacovigilance at LEO will notify the regulatory authorities and concerned 
investigators of SAEs according to the current applicable legis lation for the concerned 
countr y.  
The IRB(s)/IEC(s) will be notified of SAEs according to the current applicable legis lation for 
the concerned countr y. 
For all non -US countries, the following  reporting require ments apply: a ll SAEs which are 
assessed as causally related to the IMP(s) by [CONTACT_121580]  (ICH E2A 
Guideline), and which are unexpected ( S[LOCATION_003]Rs ), are subject to expedited reporting to 
regulatory authorities  and IEC(s) /IRB(s)  according to the current applicable legislation in the 
concerned countr y. Investigators will be notified of the evolving safety profile of the IMP  on 
an ongoing basis.  
For the US, the following  reporting requirements apply: a ll SAEs which are assessed as 
causally related to the IMP(s) by [CONTACT_82093]  (Guidance for Industry and Investigators - Safety 
Reporting Requirements for INDs and BA/BE Studies ; Guidance for Clinical Investigators, 
Sponsors, and IRBs: Adverse Event Reporting to IRBs â€“ Improving Human Subject 
Protection ) and which are unexpected ( Serious and Unexpected Suspected Adverse Reactions  
[IND safety rep ort]) are subject to expedited reporting to regulatory authorities  and IRB(s). 
Investigators will be notified of  the evolving safety profile of the IMP  on an ongoing basis.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725960] knowledge using t he (paper) Pregnancy Form (Part  I). All pregnancies must be followed 
up until delivery or termination and final outcome must be reported on t he (paper) Pregnancy 
Form (Part  II) within [ADDRESS_725961] immediately discontinue IMP permanently (Section s 10.2.1  and 10.3). 
13.[ADDRESS_725962]  
The event listed in Panel 13 is considered an AESI in this trial and will require that the 
investigator provides additional details to be recorded in the eCRF . An AESI may be serious 
(requiring expedited reporting, Section 13.4) or non -serious.  
Panel 13: Adverse events of special interest  
Adverse  event of special interest  Additional information to be provided  
Eczema herpeticum  Skin findings:  
ï‚· Lesion type . 
ï‚· Disseminated/localized . 
ï‚· Location . 
ï‚· Present in area with visible eczema/no 
visible eczema/ present in areas with and 
without eczema . 
ï‚· Monomorphic/polymorphic . 
Confirmation of herpes simplex virus . 
 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725963] using more than the recommended qua ntity of IMP 
specified in this protocol  in Section 9.2 (at the investigator â€™s discretion) . An overdose is either 
accidental or intentional.  
The term â€˜overdose â€™ including a specification of why it occurred ( accidental or intentional ) 
must be docu mented on the AE form of the eCRF. In addition , AEs originating from overdose 
must be documented  on a separate line.  If the AE originating from the overdose qualifies as 
an SAE, expedited reporting is required ( Section  13.4). 
13.6.[ADDRESS_725964]. Broadly, medication er rors fall into 
4 categories: wrong medication, wrong dose (including strength, form, concentration, 
amount), wrong route of administration , or wrong subject . 
The medication error category must be documented on the AE form in the eCRF. In addition , 
AEs originating from a medication error must be documented on a separate line.  If the AE 
originating from the medication error qualifies as an SAE, expedited reporting is required 
(Section 13.4). 
13.6.4  Misuse  
Misuse refers to situations where the IMP is intentionally and inappropriately used not in 
accordance with the protocol.  
The term â€˜misuse â€™ must be documented on the AE form in the eCRF. In addition,  AEs 
originating from misuse must be documented on a separate line.  If the AE originating from 
misuse qualifies as an SAE, expedited reporting is required ( Section 13.4). 
13.6.5  Abuse  
Abuse relates to the sporadic or persistent, intentional excessive use of an IMP which is 
accompanied by [CONTACT_3584].  
The term â€˜abuse â€™ must be documented on the AE form in the eCRF. In addition , AEs 
originating from abuse must be  documented on a separate line.  If the AE originating from 
abuse qualifies as an SAE,  expedited reporting is required ( Section 13.4). 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725965] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
13.6.6  Aggravation of condition  
Any clinically significant aggravation/exacerbation/worsening of any medical condition(s)  
(including the trial disease) , compared to basel ine, must be reported as an AE  in accordance 
with Section 13.3 and 13.4. 
13.7 Follow -up for final outcome of adverse events  
During the trial , the investigator should follow up for final outcome on all AEs (including 
SAEs). Once a subject leaves the clinical trial, the investigator should follow up on the 
outcome of all non -serio us AEs classified as of possibly /proba bly relationship to the IMP for 
[ADDRESS_725966] stabilised and ca nnot be expected to 
recover during the trial or the safety follow -up periods, for example chronic or stabilised 
conditions , â€˜not recover edâ€™ is accepted as a final outcome and a statement that the SAE has 
stabilised or is chronic  should be added to the narrative in the SAE form.   
13.8 Handling of an urgent safety measure  
An urgent safety measure is a measure taken to implement an action/protocol deviation under 
an emergency. This is defined as â€œâ€¦the occurrence of any new event relating to the conduct 
of the trial  or the development of the investigational medicinal product where that new event 
is likely to affect the safety of the subjects, the sponsor and the investigator shall take 
appropriate urgent safety measures to protect the subjects against any immediate 
hazard. â€  (EU Directive 2001/20 /EC). 
If the investigator becomes aware of information that necessitates an immediate change in the 
clinical trial procedure or a temporary halt to the clinical trial in order to protect clinical trial 
subjects from any immediate hazard to their health and safety, the investigator can do so 
without prior approva l from LEO, regulatory authorities , or IRBs/IECs . 
The investigator must immediately inform LEO â€“ by [CONTACT_552323] â€“ of this change in the clinical trial procedure or of the temporary halt 
providing full details of the information and the decision making process leading to the 
implementation of the urgent safety measure.  
LEO must act immediately upon receip t of the urgent safety measure notification in 
accordance with internal procedures  and local legislation . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725967] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
14 Statistical m ethods  
14.1 Sample size 
A total of 250 subjects will be randomis ed 1:1:1:1:1 to  one for the following 5 treatment 
groups: delgocitinib cream 1 mg/g, 3 mg/g, 8 mg/g , 20 mg/g  or delgocitinib  cream vehicle.  
The sample size is based on the following pairwise consideration, even though th e primary 
objective of the trial  is to establish the dose -response relationship: With a significance level of 
5% when comparing two treatment groups and assuming a difference in the mean change 
from baseline to Week 8 in EASI of 7 (with a standard deviation of 9  for each treatment 
group ) between an investigational dose ( delgocitinib  cream) and delgocitinib  vehicle, t hen [ADDRESS_725968] 95% to detect a 
differen ce between two treatment groups . With 35â€“40 subjects per treatment group (e.g. in the 
subgroups of subjects with moderate or severe AD), there is approxima tely 90% power to 
detect a difference of [ADDRESS_725969] from the full analysis set, a justif ication addressing ICH E9 will 
be given.  
A per protocol analysis set will be defined by [CONTACT_552324]:  
ï‚· Did not provide EASI or vIGA -AD data following start of treatment . 
ï‚· Are known to  have taken the wrong IMP throughout the treatment period  of 
the trial . 
ï‚· Did not fulfil the disease defining inclusion criteria (that is, inclusion criteria 3, 
4, 5, and 6). 
ï‚· Did not apply  IMP at least 80% of the time in the period from date of first 
applica tion of IMP to date of last application of IMP . 
A safety analysis set will be defined as all randomised subjects exposed to IMP.   

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725970] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The decisions regarding inclusion/exclusion of subjects and/or subject data from the trial 
analysis sets will be documented in  the analysis set definition document before breaking the 
randomisation code.  
14.[ADDRESS_725971] pruritus  (â€œitchâ€ â€“ one of the symptoms 
captured in ADSD) (weekly average) above/below 4 on the NRS scale  will also be given by 
[CONTACT_11338] (North America (US and Canada) and Australia) and baseline disease severity  (baseline 
vIGA -AD of 2, 3, and 4) . 
Demographics include age, sex, race , and ethnicity . Other baseline characteristics include vital 
signs, height, weig ht, body mass index, total IgE , Fitzpatrick skin classification , duration of 
AD, concurrent diagnoses (from medical history and indications for concomitant medication), 
concomitant medication, and previous AD treatments.  
14.3.[ADDRESS_725972] 
application of IMP in that period, both days included.  
Exposure to treatmen t will be presented for the safety analysis set as days of exposure per 
treatment group.  
Drug accountability data will be calculated by [CONTACT_552325]. Average weekly/bi -weekly and total u sage will be  
presented per treatment group, respectively, both for time intervals between visits (1 or 2 -
week periods depending on the time between site visits ) and total period.  
Adherence to treatment regimen will be recorded in the eCRF. If any complications or 
deviations in administration are observed, these will be described as protocol deviations.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725973] will be controlled using a family -wise error rate of 5%. 
There will be no adjustment for the multiple testing of primary and secondary endpoints, all 
p-values will be considered nominal.  
14.3.5  Analy sis of primary efficacy endpoint  
The primary endpoint , change from baseline to Week  8 in EASI , will be analysed for the full 
analysis set and for the per protocol analysis set. The per protocol analysis is regarded as 
supportive.  
For the analysis of the ch ange from baseline to Week 8 in EASI, data collected after 
permanent discontinuation of IMP or after initiation of rescue medication will not be included 
in the analysis. Missing data at Week 8 will be imputed using the MMRM predicted values 
from the below  specified model for repeated measurements . 
The MCP -Mod  approach (see e.g.  EMA Qualif ication Opi[INVESTIGATOR_215186] -Mod  or Bretz et al. 
2005  for further details of the framework) will be used to guide dose selection. The dose -
response relationship for the continuous endpoint Change from baseline to Week 8 in EASI 
will be modelled by [CONTACT_716] 3 identified candidate models. These candidate models are 
selected based on the expected dose -response .  
Linear in log: E0 + Î´ Ã— log(d  + c), 
Emax: E0 + Emax Ã— d / (ED50 + d), 
Sigmoid Emax: E0 + Emax Ã— d h/ (ED50h + d h), 
where d is the dose (incl. vehicle), E0 is the efficacy offset (anticipated vehicle effect), Emax is 
the asymptotic maximum effect, ED50 is the half -life value of Emax, h is the steepness at ED50,  
Î´ is the slope parameter, and c is a fixed offset parameter.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725974] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The models will be adjusted for the stratification variables  region and disease severity 
(baseline vIGA -AD of 2, 3, and 4).  The model parameters (ED50, h) will be prespecified a 
priori by [CONTACT_552326] â€™s dose -ranging trial QBA2 -1 
(Nakagawa et al. 2018 ). Akaike â€™s Information Criteria will be used as the goodness -of-fit 
criterion that will drive the selection of the dose -response model that fits data best while 
controlling the family -wise error rate at 5%. Based on  the selected  model, the dose -response 
relationship  will be estimated and presented with 2 -sided 95% CI. If none of the candidate 
models converge, other possibilities of models and goodness -of-fit criteria will be explored. 
The dose -response modelling will be performed  on both the total population and subject s 
having a baseline vIGA-AD of [ADDRESS_725975] -Roger approximation to estimate denominator degrees of 
freedom, and the mean modelled as follows:  
Change from baseline in EASI  
 = treatment Ã— visit + baseline EASI  Ã— visit + region + baseline vIGA-AD 
The estimates will be presented with nominal p -values and 95% CI at each visit. The primary 
comparison between each delgocitinib  dose and vehicle will be at Week 8. 
Sensitivity analysis will be performed as applicable i n order to assess the robustness of results 
of the primary analysis with respect to the retrieved data at Week [ADDRESS_725976] no retrieved data at Week 8, will all be 
considered non -responders.  
The dose -response modelling approach suggested for the primary endpoint will also be 
applied for  the binary secondary endpoints , vIGA-AD TS and EASI75 at Week 8 . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725977] 75% 
reduction in SCORAD score (SCORAD75) at Week 8, SCORAD50 at Week 8, and the 
change from baseline to Week 8 in SCORAD score will be analysed and presented for the full 
analysis set. SCORAD50 and SCORAD75 will be ana lysed using the Cochran -Mantel -
Haenszel approach as described for the analysis for the secondary binary endpoints , and the 
change from baseline to Week 8 will be analysed using the MMRM approach as described for 
the analysis for the primary endpoint . 
[IP_ADDRESS]  Analysis of p atient -reported outcomes  
The PROs POEM, DLQI, PGI-S, PGI-C, SF-36, EQ-5D-5L, WLQ  and TSQM will be 
summarised by [CONTACT_72082]. The summaries will be 
presented for the full analysis set.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725978] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The ADSD  and Ec zema -related Sleep NRS collected in the eDiaries on a daily basis (all 
individual symptoms) will be summarised over time by [CONTACT_21753]. The summaries will be presented for the full analysis set.  
The daily diary recordings of the ADSD  will be derived into discrete weekly endpoints based 
on calendar time (with the exception of W eek 8) from baseline visit, i.e.  the endpoints 
represent the nominal week and are not directly related to the actual v isit in contrast to other 
visit-based assessments. The algorithm for deriving the endpoints at each time point is 
described as follows: baseline weekly average will be defined by [CONTACT_552327] -[ADDRESS_725979] pruritus (one of the symptoms captured in 
the ADSD) (weekly average) score of â‰¥4, the proportion of subjects with reduction in worst 
pruritus (weekly average)  of â‰¥4 from baseline to Week 8 will be summarise d by [CONTACT_552328] -Mantel -Haenszel approach as described for the 
analysis of the secondary binary endpoints.  
In the subgroup of subjects with a baseline DLQI score of â‰¥4, the proportion of subjects with 
a reduction in DLQI  score of â‰¥4 at Week 8 will be summarised by [CONTACT_552329] -Mantel -Haenszel approach for the analysis of the 
secondary binary endpoints.  In addition, the proportion of subjects achieving a DLQI  score of  
0 or 1 at Week 8 will be presented .  
In the subgroup of subjects with a baseline POEM score of â‰¥4, the proportion of subjects with 
a reduction in POEM score of â‰¥4 at Week 8 will be summarised by [CONTACT_552330] -Mantel -Haensz el approach as described for the analysis of the 
secondary binary endpoints.  
The change from baseline to Week 8 in ADSD  (weekly average  for each individual symptom ), 
Eczema -related Sleep NRS (weekly average), POEM, DLQI, SF-36, EQ-5D-5L and WLQ  
will be sum marised by [CONTACT_547726], where applicable, and analysed using the 
MMRM approach as described for the analysis of the primary endpoint . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725980] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
The TSQM at Week 8 will be summarised by [CONTACT_552331] a n analysis of variance model including treatment, region and 
baseline vIGA -AD as factors.  
[IP_ADDRESS]  Efficacy over time  
To further explore possible early onset of effect and general efficacy over time, the following 
endpoints will be evaluated at each scheduled assessment up to Week  6 or each week up to 
Week  7: 
ï‚· vIGA-AD TS at each scheduled assessment until Week 6.  
ï‚· EASI75  at each scheduled assessment until Week 6.  
ï‚· Change in SCORAD from baseline to each scheduled assessment until Week  6.  
ï‚· Change from baseline to each week through Week  1 to 7 in ADSD  (weekly 
average for each individual symptom) . 
o Reduction of worst pruritus (one of the symptoms captured in 
the ADSD) (weekly average)  of â‰¥[ADDRESS_725981] 
pruritus (weekly average) of  â‰¥4.  
ï‚· Change from baseline to each week through Week  1 to 7 in Eczema -related 
Sleep NRS  (weekly average) . 
ï‚· Change in DLQI score from baseline to each scheduled assessment until 
Week  6.  
ï‚· Reduction in DLQI of  â‰¥4 from baseline to each scheduled assessment until 
Week  6 among subjects with baseline DLQI â‰¥4. 
For the binary endpoints, the same Cochran -Mantel -Haenszel test as for the Week  8 
assessment will be applied. For the continuous endpoints , the repeated measurements model 
already described previously for the Week  8 assessments facilitates that the p -values, 
treatment differences , and 95% CIs can be derived for each visit up to Week  6 (or Week  7 for 
the change in ADSD  (weekly average  for eac h individual symptom ) and Eczema -related 
Sleep NRS [weekly average] ). 
14.3.8   Analysis of pharmacodynamics and pharmacogenomics  
Exploratory analyses of biomarkers will be performed for the total population as well as by 
[CONTACT_89309].  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725982] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
A summary of the results will be included in the CTR if it is available in time for this. The full 
set of biomarker  results will be reported in an addendum report to the CTR.  
14.3.9  Analysis of safety  
The analysis of safety will be based on the safety analysis se t. 
[IP_ADDRESS]  Adverse events  
AEs will be coded during the course of the trial according to MedDRA . AEs will be presented 
by [CONTACT_552332].  
Treatment -emergent AEs will be summarised; however, all AEs recorded during the course of 
the trial will be in cluded in subject data listings. An event will be considered 
treatment -emergent if started after the first use of IMP or if started before the first use of IMP 
and worsened in severity after first dose of IMP. The tabulations described in the following 
will only include the treatment -emergent events. In each of the tabulations, AEs are defined 
by [CONTACT_421488].  
An overall summary of the number of events and the number (percentage) of subjects with 
any treatment -emergent AEs, deat hs, SAEs, premature discontinuations from the trial due to 
AEs, treatment -related AEs and severe AEs will be presented.  
The number of AEs and number of subjects with each type of AEs will be tabulated by 
[CONTACT_1570] .  
The severity for each type of AE w ill be tabulated by [CONTACT_1570]. Where there are several 
recordings of severity for a given type of AE, severity will be taken as the most severe 
recording for that AE.  
The causal relationship to IMP for each type of AE will be tabulated by [CONTACT_3148] g roup. 
Where there are several recordings of causal relationship to the IMP for a given type of AE, 
causal relationship will be taken as the most -related recording from the last report of that AE, 
since that is when the investigator will be in possession of  most information and therefore be  
best able to judge causal relationship.  
Related AEs are defined as AEs for which the investigator has not described the causal 
relationship to IMP as â€˜not related â€™. The number of subjects with each type of related AE wil l 
be tabulated .  
SAEs will be evaluated separately and a narrative for each will be given.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725983] will be tabulated by [CONTACT_552333] . 
AEs leading to withdrawal from trial and AEs leading to  permanent discontinuation of IMP 
will be tabulated by [CONTACT_552333] . 
[IP_ADDRESS]  Vital signs 
The change in vital signs (blood pressure, pulse , body temperature) from baseline to each visit 
will be summarised as mean, standard deviation, median, minimum, and maximum values for 
each treatment group.   
[IP_ADDRESS]  Clinical laboratory evaluation  
The change in each of the laboratory parameters from baseline to each visit will be 
summarised by [CONTACT_421490], standard deviation, median, minimum, and 
maxim um values.  
Laboratory parameters will be classified as â€˜lowâ€™, â€˜normal â€™ or â€˜highâ€™, depending on whether 
the value is below, within or above the reference range, respectively. A shift table will be 
produced showing the categories at baseline against those at  end of treatment. Subjects with 
laboratory parameters outside the reference range will be listed.    
[IP_ADDRESS]  Subject assessment of local tolerability  
Subject assessment of local tolerability will be summarised by [CONTACT_3232].  
14.3.[ADDRESS_725984] IMP 
application by [CONTACT_1570] .  
14.3.11   Interim analysis  
No inter im analysis is planned.  
14.3.12  General principles  
Unless otherwise stated, all significance tests will be 2 -sided using the 5% significance level. 
All CIs will be presented with 95% degree of confidence.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725985] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
An observed -cases approach will be used for tabulations of data by [CONTACT_765] (i.e. involving only 
those subjects who attended each specific visit).  
Categorical data will be summarised using the number and percentage of subjects in each 
category and treatment group. Continuous data will be summarised using the mean, me dian, 
standard deviation, minimum, and maximum values.  
All the analyses specified in the protocol will be reviewed in relation to the blinded data 
actually obtained and the statistical analysis plan will be finalised before breaking the 
randomisation code.  
Any changes from the statistical analysis planned in this clinical trial protocol will be 
described and justified in a protocol amendment, the statistical analysis plan and/or in the 
CTR dependent on the type of deviation.   
14.3.13  Handling of missing values  
Procedures for handling of missing values are included under the sections describing the 
individual analyses.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725986] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
15 References  
Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. Validation of 
a general measure of treatment satisfaction, the  Treatment Satisfaction Questionnaire for 
Medication (TSQM), using a national panel study of chronic disease. Health Qual Life 
Outcomes. 2004;2:12.   
Amano W, Nakajima S, Kunugi H, Numata Y , Kitoh A, Egawa G, Dainichi T, Honda T, 
Otsuka A, Kimoto Y , Yamamot o Y , Tanimoto A, Matsushita M, Miyachi Y, Kabashima K. The 
Janus kinase inhibitor JTE -052 improves skin barrier function through suppressing signal 
transducer and activator of transcription 3 signaling. Journal of Allergy  and Clinical 
Immunology. 2015; 136:667-677.  
Bao L, Zhang H, Chan LS. The involvement of the JAK -STAT signaling pathway in chronic 
inflammatory skin disease atopic dermatitis. JAK-STAT. 2013;2:3,e24137 . 
Bieber T. Atopic dermatitis. N Engl J Med. 2008;358(14):1483 -1494.  
Bretz F, Pi[INVESTIGATOR_144676],  Branson M. Combining Multiple Comparisons and Modeling 
Techniques in Dose -Response Studies. Biometrics. 2005;61:[ADDRESS_725987] -spectrum and targeted t herapi[INVESTIGATOR_014]. J Allergy Clin Immunol. 2017;139: 
S65-S76. 
Cardona ID, Cho SH, Leung DY . Role of bacterial superantigens in atopic dermatitis: 
implications for future therapeutic strategies. Am J Clin Dermatol. 2006;7(5):273 -279. 
Charman CR, Venn AJ, Williams HC . The patient -oriented eczema measure: development and 
initial validation of a new tool for measuring atopic eczema severity from the patients â€™ 
perspective. Arch Dermatol. 2004;140(12):1513 -1519.  
Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JI, Knigh t R. Bacterial community 
variation in human body habitats across  space and time. Science. 2009; 326(5960):1694 -1697.  
Czarnowicki T, Krueger JG, Huttmann -Yassky E. Novel concepts of prevention and treatment 
of atopic dermatitis through barrier and immune man ipulations with implications for the 
atopic march . J Allergy Clin Immunol. 2017; 139:1723 -1734.  
Eli Lilly and Company. Validated Investigator Global Assessment scale for Atopic Dermatitis. 
vIGA -ADâ„¢. CopyrightÂ© 2017 Eli Lilly and Company. Used with the permi ssion of Eli Lilly 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725988] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
and Company under a Creative Commons Attribution -NoDerivatives 4.0 International 
License. Available from: http://www.eczemacouncil.org/wp -
content/uploads/2018/02/Validated -Investigator -Global -Assessment -Scale_vI GA-
AD_2017.pdf [last asses sed 11-June-2018].  
EMA. Qualification Opi[INVESTIGATOR_215186] -Mod as an efficient statistical methodology for model -
based design and analysis of Phase II dose  finding  studies under  model uncertainty  (2014). 
http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guidel
ine/2014/02/WC500161027.pdf [last assessed  11-June-2018].  
European Parliament and Council of The European Union. Directive 2001/20/EC of [ADDRESS_725989] of 
clinical trials on medicinal products for human use [2001], article 10.  
European Task Force on Atopic Der matitis. Severity scoring of atopic dermatitis: the 
SCORAD index. Consensus report of the European task force on atopic dermatitis. 
Dermatology. 1993;186(1):23 -31. 
FDA. Attachment to discussion document for patient -focused drug development public 
workshop on Guidance 3: Select, develop or modify fit -for-purpose clinical outcome 
assessments, Appendices. 2018.  
Finlay AY , Khan GK. Dermatology Life Quality Index (DLQI) â€“ a simple practical measure 
for routine clinical use. Clin Exp Dermatol. 1994;19(3):210 -216. 
Greiner W, Weijnen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, et al. A single 
European currency for EQ -5D health states. Results from a six -country study. Eur J Health 
Econ. 2003;4(3):222 -231. 
Hanifin JM, Rajka G. Diagnostic features of atopic der matitis. Acta Derm Venereol. 1980;92: 
44-47.  
Hanifin JM, Reed ML, Eczema Prevalence and Impact Working Group. A population based 
survey of eczema prevalence in the [LOCATION_002]. Dermatitis. 2007;18(2):82 -91. 
Hanifin JM, Thurston M, Omoto M, Cherill R, Tofte SJ, Graeber M. The eczema area and 
severity index (EASI): assessment of reliability in atopic dermatitis. Exp Dermatol. 
2001;10(1):11 -18. 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725990] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Harmonising Outcome Measures for Eczema (HOME). EASI scoring table for aged 8 and 
over [homepage on the Internet]. Available from: 
http://www.nottingham.ac.uk/homeforeczema/index.aspx [last accessed 11-June-2018]. 
International Council for Harmonisation of  Technical Requirements for Pharmaceuticals for 
Human Use (ICH) 2016. Integrated addendum to ICH E6(R1): Guideline for good clinical 
practice E6(R2).  
International Ethical Guidelines for Health -related Research Involving Humans, Fourth 
Edition. Geneva. Cou ncil for International Organizations of Medical Sciences (CIOMS); 
2016.  
Kiebert G, Sorensen SV , Revicki D, Fagan SC, Doyle JJ, Cohen J, et al. Atopic dermatitis is 
associated with a decrement in health -related quality of life. Int J Dermatol. 2002;41(3):15 1-
158. 
Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA, et al. Temporal shifts in the 
skin microbiome associated with disease flares and treatment in children with atopic 
dermatitis. Genome Res. 2012;22(5):850 -859. 
Lerner D, Amick BC III, Rogers WH , Malspeis S, Bungay K, Cynn D. The Work Limitations 
Questionnaire. Med Care. 2001;39:72 -85. 
Murray PJ. The JAK -STAT signalling pathways: input and output integration. Journal of 
Immunology. 2007;178:2623 -2629.  
Nakagawa H, Nemoto O, Igarashi A, Nagata T. E fï¬cacy and safety of topi[INVESTIGATOR_318257] -052, a 
Janus kinase inhibitor, in Japanese adult patients with moderate -to-severe atopic dermatitis: a 
phase II, multicenter randomized, vehicle -controlled clinical study. Britis h Journal of 
Dermatology. 2018; 178:424 -432. 
Ong PY . New insights in the pathogensis of atopic dermatitis. Paediatric research. 2014;75: 
171-175. 
Pesu M, Candotti F, Husa M, Hofmann SR, Notaraangelo LD, O â€™Shea JJ. Jak3, severe 
combined immunodeficiency, and a new class of immunosuppressive drugs. Immu nolog Rev. 
2005;203:127 -142. 
Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated 
guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725991] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Silverberg JI, Hanifin JM. Adult eczema prevalence and associations with asthma and other 
health and demographic factors: a US population -based study. J Allergy Clin Immunol. 
2013;132(5):1132 -1138.  
Tofte SJ, Graeber M, Cherill R, Omoto M, Thurston M, Hanifin JM. Eczema area and severity 
index (EASI): A new tool to evaluate  atopic dermatitis. J Eur Acad Dermatol Venereol. 1998; 
11(suppl 2):S197.  
Ware JE Jr, Sherbourne SD. The MOS 36 -item short -form health survey (SF -36). I. 
Conceptual framework and item selection. Med Care. 1992;30(6):473 -483. 
Weidinger S, Novak N. Atopic de rmatitis. Lancet. 2016;387([ZIP_CODE])1109 -1122.  
World Medical Association 2013. Declaration of Helsinki â€“ ethical principles for medical 
research involving human subjects. 7th (Fortaleza) amendment.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725992] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 1: Definitions of adverse events and serious adverse  events  
Adverse event definition  
An AE is defined as any untoward medical occurrence in a patient or clinical investigation 
subject administered a pharmaceutical product and which does not necessarily have a causal 
relationship with this treatment. An AE can therefore be any unfavourable and u nintended 
sign (including an abnormal laboratory finding), symptom, or disease temporally associated 
with the use of a medicinal (investigational) product, whether or not related to the medicinal 
(investigational) product.  (ICH GC P Guideline ) 
This definition includes:  
ï‚· Accidental i njuries . 
ï‚· Events related to trial procedures . 
ï‚· Reasons for any unfavourable and unplanned change in  medication (drug 
and/or dose) . 
ï‚· Clinically significant worsening  of pre -existing conditions . 
ï‚· Reasons for admission to hospi[INVESTIGATOR_548813] . 
ï‚· AEs commonly observed and AEs anticipated based on the pharmacological 
effect of the IMP. 
ï‚· Any laboratory abnormality asse ssed as clinically significant by [CONTACT_1275] (see Section  11.4.4 ). 
Serious a dverse event definition  
An SAE is any untoward medical occurrence that  
ï‚· Results in death . 
ï‚· Is life -threatening . 
ï‚· Requires inpatient hospi[INVESTIGATOR_539101]. 
Planned hospi[INVESTIGATOR_548814] â€™s medical 
record . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725993] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
ï‚· Results in persistent or significant disability/incapacity . 
ï‚· Is a congenital anomaly /birth defect . 
or  
ï‚· Is a medically important condition. Events that may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_548815]. Examples are intensive treatment in an emergency 
room or at home for allergic bronchospasm , blood dyscrasias and convulsions 
that do not result in hospi[INVESTIGATOR_11956] , development o f drug dependency or drug 
abuse  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725994] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 2: Classification of adverse events  
Severity  
The severity  of the AE should  be described in terms of mild, moderate or severe according to 
the investigator â€™s clinical judgement.  
Mild  An AE that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
Moderate  An AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to the 
subject.  
Severe  An AE that interru pts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
If the severity of an AE worsens, a new AE should be recorded.  
Causality  
The causal relation  of the AE to the use of the IMP should  be described in terms of probable, 
possible , or not related according to the investigator â€™s clinical judgement. The categories are 
defined below.  
Probably 
related  Follows a reasonable temporal sequence from administration of the IMP. 
 
Could not be reasonably explained by [CONTACT_423] â€™s clinical state, 
environmental or toxic factors or other therapi[INVESTIGATOR_73258] . 
 
Follows a known pattern of response to the IMP. 
 
Disappears or decreases on cessation or reduction in dose of the IMP. 
 
Reappears or worsens upon re -challenge . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725995] â€™s clinical state, 
environmental or toxic factors or other therapi[INVESTIGATOR_552287] . 
 
Follows a known pattern of response to the IMP. 
Not related  
 Does not follow a reasonable temporal sequence from administration of the 
IMP. 
 
Is better explained by [CONTACT_73343] â€™s clinical state, 
environmental o r toxic factors or other therapi[INVESTIGATOR_73258] . 
 
Does not reappear or worsen upon re -challenge . 
 
Does not follow a known pattern of response to the IMP. 
 
Outcome  
The outcome  of the ev ent according to the investigator â€™s clinical judgement should  be 
classified  using the categories below.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725996] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Recovered/  
resolved  The event has stopped. The stop date of the event must be recorded.  
Recovering/  
resolving  The subject is clearly recovering from an event. The event is not yet 
completely resolved.  
Not 
recovered/  
not resolved  Event is still ongoing.  
Recovered /   
resolved  with 
sequelae  The event has reached a state where no further changes are expected and the 
residual symptoms are assumed to persist. An example is hemiparesis after 
stroke.  
 
The stop date of the event must be recorded. In case of a SAE, the sequelae 
should be specified.  
Fatal  The subject has died as a consequence of the event. Date of death is recorded 
as stop date for the AE.  
Unknown  Unknown to investigator, e.g. subject lost to fol low-up. 
 
Note that as per the above definition, LEO uses â€œRECOVERED/RESOLVED â€ only if an 
event has actually stopped. According to the CDISC definition, the category 
â€œRECOVERED/RESOLVED â€ also includes events which have improved. However, 
following the LEO definitions above, such an improved event will instead be classified as 
â€œNOT RECOVERED/NOT RESOLVED â€ or â€œRECOVERING/RESOLVING â€. 
Similarly, it should be noted that as per the above definition, LEO uses 
â€œRECOVERED/RESOLVED WITH SEQUELAE â€ only if an event has reached a state where 
the residual symptoms are assumed to persist. According to CDISC, an event is considered 
â€œWITH SEQUELAE â€, if it has â€œretained pathological conditions â€. Consequently, it is likely 
that some of the events classified by [CONTACT_552334] â€œRECOVERED/RESOLVED 
WITH SEQUELAE â€ could have been classified with the outcome 
â€œRECOVERED/RESOLVED â€ according to the CDISC definition.  
For SAEs which have stabilised and cannot be expected to recover during study or safety 
follow -up periods, for example chronic illnesses, the final outcome should be considered to be 
â€˜recovered â€™ and a statement that the SAE has stabilised shoul d be added to the narrative in the 
SAE form. Please note that the event should not be reported as â€˜recovered â€™ on the SAE form.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725997] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix  3: Trial  governance considerations  
Appendix 3 A: Regulatory and ethical considerations  
This trial will be conducted in accordance with the protocol and with the following:  
ï‚· Consensus ethical principles derived from international guidelines including 
the current version of the Declaration of Helsinki  and CIOMS International 
Ethical Guidelines . 
ï‚· Current version of a pplicable  ICH GCP Guidelines . 
ï‚· EUâ€™s General Data Protection Regulation 2016/679 of 27 April 2016 . 
ï‚· Applicable laws and regulations . 
The appropriate regulatory authorities  must be notified of/approve the clinical trial as 
required.  
Any documents that  the IRB/IEC may need to fulfil  its responsibilities (such as the trial 
protocol, protocol amendments, Investigator â€™s Brochure, subject information leaflet, informed  
consent forms, or advertisements) will be submitted to the IRB/IEC. These documents must 
be reviewed and approved by [CONTACT_1201]/IEC before the trial is initiated . 
Any amendments to the protocol must be approved by/receive favourable opi[INVESTIGATOR_552288]/IECs , as required , prior to implementation.  
The principal investigator [INVESTIGATOR_184729] , if required by [CONTACT_71882] : 
ï‚· Providing written summaries of the status of the trial to the IRB/IEC annually 
or more frequently in accordance with the requirements, policies, and 
procedures established by [CONTACT_1201]/IEC . 
ï‚· Notifying the local IRB/IEC of SAEs or other significant safety findings as 
required by [CONTACT_1744]/IEC procedures . 
ï‚· Providing oversight of the conduct of the trial at the trial site and adherence to 
applicable national and international legislation . 
Appendix 3B: Informed c onsent process   
Subjects will receive written and verbal information concerning the clinical trial. This 
information will emphasise that participation in the clinical trial is voluntary and that the 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725998] â€™s signed and dated informed consent to participate in the clinical trial will be 
obtained prior to any clinical trial related procedure being carried out in accordance with ICH -
GCP (4.8) and all applicable laws and regulations.  The autho rised person obtaining the 
informed consent must also sign the ICF.  
Subjects  will be re -consented to the most current version of the ICF(s) during their 
participation in the trial, if applicable . 
A copy of the ICF(s) must be provided to the subject .  
Subject card  
At screening, subjects will be provided with a card stating that they are participating in a 
clinical trial and which contains contact [CONTACT_49761](es) and telephone number(s) of relevant trial 
site staff including the number for the investigator i n case of emergency situations. The 
subject card also includes a local telephone number for the emergency unblinding CRO to be 
used if the investigator or delegated site staff cannot be reached or if unblinding in the IRT 
cannot be performed.  
Appendix 3 C: Subject and data confidentiality  
This clinical trial protocol as well as all other information, data , and results relating to this 
clinical trial and/or to the IMP  is confidential information of LEO and shall not be used by [CONTACT_421497].  
The investigator agrees that LEO may use any and all information, data , and results from this 
clinical trial in connection with the development of the IMPs  and, therefore, may disclose 
and/or transfer information, data and/or results to other investigators, regulatory authorities 
and/or commercial partners.  
Trial s ubjects will be assigned a unique identifier (subject  ID) by [CONTACT_82093] . Any subject â€™s records 
or data sets that are transferred to LEO will contain the identifier only; subject names or any 
information which would make the subject identifiable will not be transferred.  
Trial s ubject s must be informed and consent to that their personal trial-related data wi ll be 
used by [CONTACT_552335].   

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_725999] be informed and consent to that their medical records may be examined by 
[CONTACT_483642] , by 
[CONTACT_6667]/IEC members, and by [CONTACT_6668].  
Processing of personal data 
This protocol specifies the personal data on trial subjects ( for example race, age, gender, 
health condition, medical history, test results, etc.) which  shall be collected as part of the 
clinical trial and processed during and after trial completion.  
Personal data collected as part of the clinical trial will be transferred to/from the 
institution/investigator , LEO  and third parties acting on behalf of LEO.  
Processing of personal data on behalf of LEO requires a written agreement between LEO and 
the relevant party which covers collection, processing and transfer of personal data in the 
clinical trial. In certain cases, an agreement on transfer of personal data may also be required.  
Investigators and LEO must ensure that collection, processing and transfer of personal data 
are in compliance with applicable legislation on data protection and privacy , including but not 
limited to the EU General Data Privacy Regulation . 
Subjects must be asked to consent to the collection, processing and tran sfer of their personal 
data to EU and non -EU countries for the purpose of conducting the clinical trial, research and 
development of new or existing products/services, improving existing products/services, 
applying for marketing authorisations for products/services, marketing of products/services 
and other related activities.  
LEO has obtained the necessary authorisations for the process ing of person al data collected in 
the trial.  
Appendix 3D: Record keepi[INVESTIGATOR_007] , quality control,  and data handling  
Source d ata 
For all data recorded, the source document must be defined in a source document agreement 
or similar document at each trial site. There must only be [ADDRESS_726000] â€™s medical record or other 
defined document normally used at the trial site. Source data not normally collected as a 
routine part of the clinical practice at the site may be entered on a worksheet. Clinical 
assessments/safety evaluations must be si gned by [CONTACT_73347].  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726001] â€™s medical record, the following should as 
a minimum be added to the subject â€™s medical record:  
ï‚· Date(s) of conducti ng the informed consent process,  including date  of 
provision of subject information . 
ï‚· A statement from the investigator to verify that each of the eligibility criteria 
are met  and documented . 
ï‚· Subject ID . 
ï‚· The fact that the subject is participating in a clinical trial in AD including 
treatment arms of delgocitinib  cream (1, 3, 8 0r 20 mg/g) or delgocitinib  cream 
vehicle  for 8 weeks  plus 2 weeks of follow -up. 
ï‚· Other relevant medical information . 
Trial monitoring  
During the course of the trial , CRA(s)  will visit the trial site. These visits have the following 
objectives: (i) to continually verify source data to confirm that data entered into the eCRF by 
[CONTACT_18029], complete, and verifiable from source documents; (ii) to 
confirm that the safety and rights of subjects are being protected; and (iii) to confirm that the 
trial is being conducted in accordance with the currently approved protocol and any other trial 
agreements, ICH -GCP, and all applicable regulatory requirements.  
The mon itoring visit intervals will depend on the  trial site â€™s recruitment rate and the 
compliance of the trial site with the protocol and ICH GCP.  
In order to perform their role effectively, CRAs and persons involved in quality assurance and 
inspections will nee d direct access  to source data, e.g. medical records, laboratory reports, 
appointment books, etc. If the electronic medical record does not have a visible audit trail, the 
investigator must provide the CRA with signed and dated printouts. In addition, rele vant site 
staff should be available for discussions at monitoring visits and between monitoring visits 
(e.g. by [CONTACT_756]).  
Protocol compliance  
Protocol  deviations will be documented and notified to the investigator . Protocol deviations 
will be assessed by [CONTACT_552336].  
Sponsor audits, IRB/IEC review, and regulatory agency inspections  
The clinical trial will be subject to audits conducted by [CONTACT_552337] m IRBs/IECs. Audits and inspections may take place 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726002] been evaluated.  
Risk mitigation activities for endpoints include:  
ï‚· Ensuring  consistent data with respect to investigator assessment of effica cy 
(EASI , vIGA-AD and SCORAD), all assessors  will receive training and 
whenever possible , the efficacy assessments will be made by [CONTACT_552338] a given subject to reduce inter -rater variability . 
ï‚· Ensuring subjects and investigational staff are well instructed and trained about 
the use of the eDiary and the eDevice which will be used to collect the PROs 
(ADSD , Eczema -related Sleep NRS, POEM, DLQI, PGI-S, SF-36, EQ-5D-5L, 
WLQ, and TSQM ). 
ï‚· Ensuring investigational staff are well instructed and trained in collecting 
biomarker samples . 
ï‚· Ensuring administration of IMP is controlled and documented at the site. This 
will be done by [CONTACT_552339] t rial sites . 
ï‚· Ensuring that trial sites are well trained in safety procedures such as collection 
and reporting of adverse events . 
Throughout the trial, data quality review meetings will be held to ensure that data collections 
can be improved and mistakes pre vented. During monitoring visits to the trial sites, the CRAs 
will verify that investigators work according to the protocol.  
Data handling  
Data will be collected by [CONTACT_552340] o r 
designee electronically (e.g.  laboratory data). The investigator or staff authorised by [CONTACT_552341]. Data recorded in the eCRFs will be accessible 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726003] verify the correctness of the data entered by [CONTACT_547736]. This signature [CONTACT_552347] d. Any correction(s) made by [CONTACT_547737]. Changes to data a lready 
approved will require re-signature [CONTACT_3265] [CONTACT_093]. The person making the change to t he 
data, and the date, time and reason for the change will be identified in the audit trail.  
Subject data should be entered into the eCRF no later than 5  working days after each visit , 
unless a different  deadline is stated in the Clinical Trial Agreement. Queries for discrepant 
data will be generated automatically by [CONTACT_483646] , 
sponsor â€™s medical expert,  or the data manager. All queries will be raised electronically within 
the electronic data capture  system. This systematic validation will ensure that a clean and 
consistent database is provided for the statistical analysis.  
An ePRO solution will be used to  capture patient -reported data ( data from questionnaires 
completed at the trial site and eDiary data ). By [CONTACT_552342] , data will be 
available immediately after data entry and available for monitors and site personnel, including 
the investigator, with read access only.  The ePRO system is a separate application from the 
eCRF and data captured from th e eCRF and the ePRO will be stored on different servers 
during data capture. Data from both systems will be included in the final trial data base.  
External data transfers from vendors to LEO will be transmitt ed and handled via a secure file 
transfer protoco l site. Transmissions of electronic data from external data providers and of 
ePRO data to the clinical database are illustrated in Panel 14. 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726004] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Panel 14: Transmission of electronic data  
 
Abbreviations: CTR, clinical trial report; ECG, electrocardiogram; eCRF, electronic case report form; ePRO, 
electronic patient -reported outcome  
 
Archiving of trial documentation  
The investigator at  each trial site must make arrangements to  store the essential trial 
docu ments , including the investigator trial file (EU Directive 2001/20/EC ). Essential trial 
documents must be stored until LEO informs the investigator that the documents are no 
longer to be retained , or longer if required by [CONTACT_427].  
In addition, the investigator is responsible for the archiving of all relevant source documents 
so that the trial data can be compared against source data after the complet ion of the trial ( for 
example  in case of an inspection from regulatory authorities).  
The investigator is required to ensure the continued storage of the documents even if the 
investigator leaves the trial site or retires before the end of the required stor age period.  
No documents may be destroyed during the retention period without the written approval of 
LEO . No documents  may be transferred to another location or party without written 
acceptance from LEO . 
The destruction process must ensure confidentiality  of data and must be done in accordance 
with local regulatory requirements.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726005] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
For archiving purposes, each inves tigator will be supplied with an electronic copy of the 
eCRFs and ePRO data for all screened and randomised subjects enrolled at the trial site. This 
is done after completion of the trial and before access to the eCRF/ePRO is revoked. Audit 
trail information will be included. eCRFs and ePRO data  must be available for inspection by 
[CONTACT_552343], from regulatory authorities and/or IRBs / IECs . 
Appendix 3 E: Registration, reporting and publication policy  
Trial disclosure  
LEO is committed to be transparent with respect to its clinical trials.  
Basic information of this clinical trial will be registered in  the global data registry, 
www.ClinicalT rials.gov before the first subject enters into the trial. The trial may also become 
registered in other online data registries, according to applicable law and regulations.  
Results of this clinical trial will be posted on the corporate websi te of LEO in accordance with 
its Position on Public Access to Clinical  Trial Information no later than [ADDRESS_726006] to th e following notice requirements:  
Prior to submission for publication o r presenting a manuscript relating to the clinical trial, the 
investigator shall provide to LEO a copy of all such manuscripts  and/or presentation s. LEO 
shall  have rights to review and comment. The i nvestigator shall consider comments  by [CONTACT_552344]/or presentation based on such comments, 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726007] of LEO remove any confide ntial 
information (other than results generated by [CONTACT_093]) prior to submitting or presenting 
the manuscripts. The investigator shall, upon the request of LEO  withhold  the publication or 
presentation to allow LEO to protect its inventions and othe r intellectual property rights 
described in any such manuscripts.  
In case no multi -centre publication has been made public at the time of investigator â€™s 
notification  of an independent publication to LEO , LEO and the writing group may also delay 
the public ation or presentation if the manuscript is deemed to harm the ongoing multi -centre 
publication.  
In case of publications made by [CONTACT_121630] -centre publication has 
been published, the above -mentioned requirements must still be fol lowed.  
Any publication must comply with GPP3 standards.  
LEO complies with Good Publication Practice ( GPP3 ) standards and the recommendations 
from the International Committee of Medical Journal Editors. LEO complies with the 
positions of the International F ederation of Pharmaceutical Manufacturers & Associations, 
European Federation of Pharmaceutical Industries and Associations, Japan Pharmaceutical 
Manufacturers Association, Pharmaceutical Research and Manufacturers of America, and the 
joint position statem ent by [CONTACT_483648], the European Medical 
Writers Association, and the International Society for Medical Publication Professionals on 
disclosure of information about clinical trials, trial results and authorship. LEO also follow s 
the CONSORT reporting guidelines (Schulz et al. 2010 ). 
Appendix 3 F: Insurance  
LEO has taken out relevant insurances covering the subjects in the present clinical trial in 
accordance with applicable laws and regulations.  
Appendix 3 G: Financial disclosure  
Investigators will provide LEO with sufficient, accurate financial information as requested to 
allow LEO to submit complete and accurate financial certification or disclosure statements to 
the appropriate regulatory author ities. Investigators are responsible for providing information 
on financial interests during the course of the clinical trial and for 1  year after completion of 
the clinical trial, or for a longer period of time if required by [CONTACT_19666].  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726008] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 3 H: Trial  and s ite closure  
Premature termination of trial or trial site 
LEO, the investigator, the IRB/IECs or competent authorities may decide to stop the clinical 
trial, part of the trial or a trial site at any time, but agreement on procedures to be followed 
must be obtained.  
If a clinical trial is suspended or prematurely terminated, the investigator must inform the 
subjects promptly and ensure appropriate therapy and follow -up. As specified by [CONTACT_44536], the investigator or LEO must promptly inform IRB/IECs and 
provide a detailed written explanation. Relevant competent authorities must be informed.  
The trial must be terminated if the perception of the benefit/risk ratio (judged from clinical 
signs and symptoms, (S)AEs and/or remarkable safety laboratory changes) becomes 
unfavourable for the continuation of the trial.  
Reasons for the early closure of a trial site by [CONTACT_421510]:  
ï‚· Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, LEO â€™s procedures, or GCP guidelines.  
ï‚· Inadequate recruitment of subjects by [CONTACT_093].  
Completion of trial  
Investigators will be informed when subject recruitment is to cease.  Screening act ivities will 
be stopped at a trial site when the total requested number of subjects for the clinical trial has 
been obtained, irrespective of the specific site â€™s planned inclusion number.  
Trial sites will be closed upon trial completion. LEO will undertake  arrangements for the 
collection and disposal of any unused trial material that the investigator is not required to 
keep in his/her files.  A trial site is considered closed when all required documents and trial 
supplies have been collected and a trial site  closure visit has been performed.  
When the randomisation code has been broken, the investigators will receive information 
about the treatment allocation for the subjects randomised at their respective sites and will be 
asked to record this in the subject â€™s medical record.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726009] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 3 I: Responsibilities  
The signatory investigator is responsible for the approval of the clinical trial protocol  and 
the CTR on behalf of all clinical trial investigators and as agreed to in a Signatory Investigator 
Agreement.  
The national coordinating investigator s are responsible for national issues relating to the 
clinical trial as agreed to in a National Coordinating Investigator [INVESTIGATOR_65908].  
Each participating investigator  is responsible for all aspects of the clinical trial cond uct at 
his/her trial site as agreed to in a Clinical Trial Agreement.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726010] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 4: Short version of  eligibility criteria  
This appendix provides a short form (maximum 200 characters) of each of the eligibility 
criteria to be used when data are submitted to regulatory authorities in CDISC format.  
No. Inclusion criteria  
1 Signed and dated informed consent has been obtained prior to any protocol related procedures.  
2 Age 18 years and above . 
3 Diagnosis of AD as defined by [CONTACT_85792] ( Hanifin & Rajka 1980 ). 
4 History of AD for 1 year or more . 
5 AD involvement of 5 â€“50% treatable  body surface area at screening and at baseline (excluding scalp) . 
6 Disease severity graded as mild to severe according to vIGA -AD (i.e. vIGA -AD of 2 or more ) at screening and at 
baseline . 
[ADDRESS_726011] application of IMP.  
 
No. Exclusion criteria  
1 AD lesion(s) on scalp  at screening and /or baseline . 
[ADDRESS_726012] dermatitis that is lik ely to interfere with the assessment of severity of AD . 
4 Use of tanning beds or phototherapy (NBUVB, UVB, UVA1, PUVA) within 4 weeks prior to baseline . 
5 Systemic t reatment with immunosuppressive/ modulating drugs  or corticosteroids  within [ADDRESS_726013] of care therapy . 
14 Clinically significant infection  (systemic infection or serious skin infection requiring parenteral treatment)  within 
4 weeks prior to baseline .  
15 Tuberculosis requiring treatment within the 12 months prior to screening  and/or subjects with a positive blood test 
for tuberculosis at screening (subjects with high risk of latent tuberculosis must be tested) .  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726014] taking antiretroviral medications .  
17 Major surgery within 8 weeks prior to screening, or planned in -patient surgery or hospi[INVESTIGATOR_552289] . 
18 History of cancer . 
19 Any disorder, which  is no t stable , and  in the investigator â€™s opi[INVESTIGATOR_552290], i nfluence 
the results of the trial  or impede the subjectâ€™s ability to complete the trial . 
20 Any abnormal finding , which in the investigatorâ€™s opi[INVESTIGATOR_552291] p ut the subject at risk , influence the results of the 
trial or influence the subjectâ€™s ability to complete the trial . 
[ADDRESS_726015] negative HBsAg and HBcAb . 
22 Alanine aminotransferase or as partate aminotransferase level 2.0 times the upper limit of normal range or more at 
screening . 
23 Known or suspected hypersensitivity to any component(s) of the IMP . 
[ADDRESS_726016] of the trial, or immediate family 
members of such individuals . 
28 Legally institutionalised . 
29. Pregnant or lactating . 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726017] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 5: Contact [CONTACT_73366] , appointed CRA, and sponsor â€™s medical expert [INVESTIGATOR_548910] a separate contact [CONTACT_4111].  
Sponsor  
LEO Pharma A/S  (referred to as â€˜LEO â€™ or â€˜the sponsor â€™ in this clinical trial protocol) is the 
sponsor of the clinical trial:  
LEO Pharma A/S  
Industriparken 55  
DK-2750 Ballerup  
Denmark  
  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726018] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 6: Hanifin and Rajka (1980) diagnostic criteria for AD  
From Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol. 
1980;92:  44-47 (Hanifin & Rajka 1980 ).  
Must have 3 or more basic features : 
ï‚· Pruritus . 
ï‚· Typi[INVESTIGATOR_22784]:  
o Flexural lichenification or linearity in adults . 
o Facial and extensor involvement in infants and children . 
ï‚· Chronic or chronically -relapsing dermatitis . 
ï‚· Personal or family history of atopy (asthma, allergic rhinitis, atopic dermatitis) . 
 
Plus 3 or more minor features : 
ï‚· Xerosis . 
ï‚· Ichthyosis, palmar hyperlinearity, or keratosis pi[INVESTIGATOR_22785] . 
ï‚· Immediate (type 1) skin -test reactivity . 
ï‚· Elevated  serum IgE . 
ï‚· Early age of onset . 
ï‚· Tendency toward cutaneous infections (especially S. aureus  and herpes 
simplex )/impaired cell -mediated immunity . 
ï‚· Tendency toward non -specific hand or foot dermatitis . 
ï‚· Nipple eczema . 
ï‚· Cheilitis . 
ï‚· Recurrent c onjunctivitis . 
ï‚· Dennie -Morgan infraorbital fold . 
ï‚· Keratoconus . 
ï‚· Anterior subcapsular cataracts . 
ï‚· Orbital darkening . 
ï‚· Facial pallor/ facial erythema . 
ï‚· Pi[INVESTIGATOR_80166] . 
ï‚· Anterior neck folds . 
ï‚· Itch when sweating . 
ï‚· Intolerance to wool and lipid solvents . 
ï‚· Perifollicular accentuation . 
ï‚· Food intolerance . 
ï‚· Course  influenced by [CONTACT_222224]/ emotional factors . 
ï‚· White  dermographism/ delayed blanc .  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726019] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Appendix 7: Protocol amendment history  
The  protocol amendment summary of changes table  for the current amendment is located 
directly before the table of contents.  
Amendment 1 (09-Jan-2019 ) 
This amendment is considered to be substantial based on the criteria set forth in Article 10(a) 
of Directive 2001/20/EC of the European Parliament and the Council of the European Union 
or subsequent regulation.  
Overall rationale for the amendment  
The main reason for the amendment is to address comments to the protocol received from the 
US Food and Drug Administration. Miscellaneous other changes/updates have also been 
implemented.  
The table below summarises changes made in each section and a brief rationale for each 
change.  
Section no. and name  [CONTACT_18054] 1  
Protocol synopsis  Change of treatment success 
abbreviation fro m vIGA -AD 0/1 to 
vIGA -AD TS.  
Patient Global Impression of 
Change (PGI -C) has been added to 
the list of subject assessments of 
efficacy and health -related quality 
of life; PROs.  
Subject assessment of local 
tolerability has been added as a 
safety assessment.  
Revision of exclusion criterion on 
tuberculosis  to also include 
subjects with a positive blood test 
for tuberculosis at screening. 
Subjects with high risk of latent To reflect changes in the 
protocol.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726020] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Section no. and name  [CONTACT_552348] (e.g. prior residence in 
or travel to countries with high 
prevalence of tuber culosis, close 
contact [CONTACT_4490] a person with active 
tuberculosis, or a history of active 
or latent tuberculosis where an 
adequate course of treatment 
cannot be confirmed) must be 
tested.  
Section 4  
Schedule of trial 
procedures  Assessment of PGI -C added.  
 
 
 
 
 
 
Assessment of vital signs 
(including body temperature) 
added at Visits 4, 5, 6, and 7.  
 
Tuberculosis test added.  
 
 
 
 
 
 
 
 
 
 
 
 
 Added as a PRO anchor 
scale to generate a threshold 
for improvement that 
represents a meaningful 
amount of change in the 
target population.  
 
To include an active 
assessment for infection at 
all on -site visits.  
 
To reflect that subjects with 
high risk of latent 
tuberculosis (e.g. prior 
residence in or travel to 
countries with high 
prevalence of tuberculosis, 
close cont act with a person 
with active tuberculosis, or a 
history of active or latent 
tuberculosis where an 
adequate course of treatment 
cannot be confirmed) must 
be tested.  
 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726021] assessment of local 
tolerability 
(stinging/burning) in the  
trial.  
 
To correct inconsistency 
between protocol text and 
eCRF and to reflect how 
data is captured in the eCRF.  
 
 
 
To clarify that it is not the 
intention that full medical 
history is to be recorded 
both at screening and at 
baseline.  
 
To clarify that on ly subjects 
with a paid job are to answer 
the WLQ.  
Section 6  
Trial objectives and 
endpoints  Change of treatment success 
abbreviation from vIGA -AD 0/1 to 
vIGA -AD TS.  
 
 
 
 
 
 
The endpoint Change in PGI -S 
from baseline to Week 8 has been 
deleted.  To avoid misu nderstandings 
between a vIGA -AD score 
of 0 (clear) or 1 (almost 
clear) and vIGA -AD 
treatment success defined as 
an IGA score of 0 (clear) or 
1 (almost clear) with at least 
a 2-step improvement.  
 
Due to an update of the 
wording of the PGI -S 
questionnaire (s ee Section 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726022] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Section no. and name  [CONTACT_111444]  
[IP_ADDRESS]), the sample size for 
the updated PGI -S will 
likely not be sufficient to 
perform a statistical analysis. 
PGI-S will still be 
summarised descriptively 
and used as an anchor scale.  
Section 8.[ADDRESS_726023] for tuberculosis 
at screening. Subjects with high 
risk of latent tuberculosis (e.g. 
prior residence in or travel to 
countries with high prevalence of 
tuberculosis, close contact [CONTACT_4490] a 
person wi th active tuberculosis, or 
a history of active or latent 
tuberculosis where an adequate 
course of treatment cannot be 
confirmed) must be tested.  To further safeguard subjects 
in risk of (re)activation of 
latent tuberculosis.  
Section 9.[ADDRESS_726024] of prohibited medication  and 
procedures  (prohibited from 4 
weeks prior to baseline to end of 
trial).  
 
Wet wraps have been added as an 
example of topi[INVESTIGATOR_12969] 
(drug, non -drug) not allowed on 
lesional skin.  To clarify that bleach baths 
are not allowed.  
 
 
 
 
To provide example of 
topi[INVESTIGATOR_552292].  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726025] been 
added:  
Any infection that is opportunistic, 
such as active tuberculosis and 
other infections whose nature or 
course may suggest an immuno -
compromised status.  
Lymphopenia (lymphocytes 
<0.5x109/l; grade 3 according to 
CTCAE v5.0) confirmed by 
[CONTACT_260055] [ADDRESS_726026] subjects 
in case of opportunistic 
infections and/or 
lymphopenia.  
Section 11.1  
Overview  Panel 6 has been revised:  
 
â€œInvestigator assessments â€ has 
been changed to â€œEfficacy 
assessments by [CONTACT_093] â€.  
 
Box with text: â€œBaseline visit (Day 
1) only: Check cappi[INVESTIGATOR_552293] â€ has 
been deleted.  
 
â€œSafety and laboratory 
assessments â€ has been changed to 
â€œSafety assessments by [CONTACT_1275] â€. 
 
A new box after â€œSafety 
assessments by [CONTACT_11168] â€ 
has been added: â€œSubject 
assessment of local tolerability â€.  
 
For clarification.  
 
 
 
Cappi[INVESTIGATOR_552294] A/S.  
 
 
For clarification.  
 
 
 
 
To reflect that subject 
assessment of local 
tolerability is added to the 
trial and that assessment 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726027] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Section no. and name  [CONTACT_111444]  
 
 
 
 
â€œOther assessments â€ has been 
changed to â€œLaboratory and other 
assessments â€. should be performed after 
safety assessments by [CONTACT_1275].  
 
For clarification.  
Section 11.4.4  
Laboratory testing  Panel 11 (Clin ical laboratory tests):  
 
Interferon gamma release test has 
been added.  
 
 
 
C-reactive protein has been added .  
 
Added to test for 
tuberculosis in subjects with 
high risk of latent 
tuberculosis.  
 
Added as an active 
assessment for infection . 
Section 11.4.[ADDRESS_726028] assessment of local 
tolerability 
(stinging/burning) in the 
trial.  
Section 11.6.3  
Skin biopsies and 
photographs (all sites, 
but optional)  It has been added that biopsies will 
not be taken if the investigator 
considers the procedure unsuitable 
for the subject (e.g. subjects 
receiving anticoagulant therapy).  
 
It has been deleted that no further 
biopsies will be taken after 
biopsies from [ADDRESS_726029].  
 
 
The data from the analysis 
of the biopsies will af ter 
completion of this trial be 
shared with the Innovative 
Medicines Initiative (IMI) 
consortium, BIOMAP. I n 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726030] likely 
need full transcriptomics 
dataset  for their disease 
characterisation. For this 
reason, some of the biopsies 
(biopsies obtained at 
baseline) will undergo 
transcriptomics profiling.  
Section 11.7.1  
Patient -reported 
outcomes (PROs)  PGI-C added to the list of PROs to 
be completed in the elect ronic 
device by [CONTACT_748]. The number 
of PROs to be completed has 
changed from [ADDRESS_726031] the addition of 
PGI-C assessment in the 
trial. 
Section [IP_ADDRESS]  
Patient Global 
Impression of Severity 
(PGI -S) Wording of PGI -S questionnaire 
has been updated.  As per advice from the U S 
Food and Drug 
Administration . 
Section [IP_ADDRESS]  
Patient Global 
Impression of Change 
(PGI -C) New section.  To reflect the addition of 
PGI-C assessment in the 
trial. 
Section [IP_ADDRESS]  
Work Limitation 
Questionnaire (WLQ)  It has been added that the WLQ 
will be completed at the trial site 
for subjects with a paid job.  To clarify that only subjects 
with a paid job are to answer 
the WLQ.  

Trial ID: LP0133 -1275 Date : 22-Aug-2019  Version: 3.[ADDRESS_726032] visit attended.  Reasons for permanent 
discontinuation of IMP and 
withdrawal from trial will be 
presented by [CONTACT_243688].  
Section 14.3.4  
Testing strategy  
 
Section 14.3.6  
Analysis of secondary 
efficacy endpoints  
 
Section [IP_ADDRESS]  
Efficacy over time  Change of treatment success 
abbreviation from vIGA -AD 0/1 to 
vIGA -AD TS.  To avoid misunderstandings 
between an vIGA -AD score 
of 0 (clear) or 1  (almost 
clear) and vIGA -AD 
treatment success defined as 
an IGA score of 0 (c lear) or 
1 (almost clear) with at least 
a 2-step improvement.  
Section [IP_ADDRESS]  
Analysis of patient -
reported outcomes  PGI-C has been added to the list of 
PROs to be summarised by 
[CONTACT_94154].  
 
Time interval calcu lations of 
weekly average of ADSD have 
been revised (e.g. baseline weekly 
average of ADSD will be defined To reflect the addition of 
PGI-C assessment in the 
trial. 
 
 
The approach for calculation 
of weekly average has been 
revised since ADSD is 
completed in the  evening 

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726033] PARTY WITHOUT 
THE PRIOR WRITTEN CONSENT OF THE LEO GROUP  
 
Section no. and name  [CONTACT_552349] [CONTACT_552345] -7 to Day -1 instead of from 
Day -6 to Day 1) and text has been 
slightly revised.  
 
The description of how to analy se 
PGI-S has been deleted.  
 
 throughout the trial . 
 
 
 
 
PGI-S has been deleted as an 
endpoint and will only be 
summarised descriptively.  
Section [IP_ADDRESS]  
Adverse events  It has been added that adverse 
events of special interest will be 
tabulated by [CONTACT_552346] . 
 
AEs leading to withdrawal from 
trial and AEs leading to  permanent 
discon tinuation of IMP will be 
tabulated by [CONTACT_1570]. No 
narratives will be made for these 
AEs.  To clarif y how adverse event 
of special interest will be 
summarised.  
 
 
AEs leading to withdrawal 
from trial and AEs leading to 
permanent discontinuation 
of IMP , as well as  AEs of 
special int erest will be 
tabulated and listed as this is 
a more informative way of 
prese nting data on these 
event types.  
Section [IP_ADDRESS]  
Subject assessment of 
local tolerability  New section.  To describe statistical 
handling of the subject 
assessment of local 
tolerability.  
Appendix [ADDRESS_726034] for tuberculosis 
at screening (subjects with high To further safeguard subjects 
in risk of (re)activation of 
latent tuberculosis.  

Trial ID: LP0133 -1275  Date : 22-Aug-2019  Version: 3.[ADDRESS_726035] be 
tested).  
Throughout  Minor editorial and document 
formatting changes.  Minor, have therefore not 
been summarised.  
 
 
 

6LJQDWXUH3DJHIRU70)Y
(OHFWURQLFVLJQDWXUHVPDGHZLWKLQH70)/(2DUHFRQVLGHUHGWREH D
OHJDOO\ELQGLQJHTXLYDOHQWRIWUDGLWLRQDOKDQGZULWWHQVLJQDWXUH V5HDVRQIRUVLJQLQJ$SSURYHG 0DQDJH DG HU9HUGLFWV
1DPH  &DSDFLW'DWHRIVLJQDWXUH$XJ*07
5HDVRQIRUVLJQLQJ$SSURYHG 0DQDJH $S 9HUGLFWV
1DPH  &DSDFLW V'DWHRIVLJQDWXUH$XJ*07
5HDVRQIRUVLJQLQJ$SSURYHG 0DQDJH $ U9HUGLFWV
1DPH  &DSDFLW'DWHRIVLJQDWXUH$XJ*07PDD
PDD PDDPDD
PDD PDD